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ROLE OF TRANSCRIPTION FACTOR MEF2A IN DEVELOPMENT OF 
CORONARY ARTERY DISEASE (CAD) AND 
MYOCARDIAL INFARCTION (MI) 
 
MANI RAGAVA SAIKRISHNA BHAGAVATULA 
 
ABSTRACT 
 
   Coronary artery disease (CAD) and myocardial infarction (MI) are the leading 
cause of death in developed countries. Genetic factors play an important role in the 
pathogenesis of CAD and MI. The revolutionary advances in molecular genetics have 
provided new insights into the genetic pathways involved in this disease. Recently, our 
laboratory used linkage analysis to map the first disease-causing gene for CAD and MI to 
chromosome 15q26 in a large family and subsequently mutation analysis identified a 7-
amio acid deletion in MEF2A, a gene encoding a transcription factor. Later we identified 
three novel mutations N263S, P279L, G283D in four other patients or families, which has 
validated our initial finding of MEF2A as a gene for CAD and MI.  
  We recently screened another set of 200 CAD and MI patients using the single 
strand conformation polymorphism (SSCP) method and found another variant, T215A, in 
the sixth coding exon of MEF2FA in one CAD patient.  The T215A mutation is clustered 
close to the major transcriptional activation domain of MEF2A.We then performed 
functional studies using the luciferase assay and found that the mutation significantly 
reduced the transcriptional activity of MEF2A and acted by a loss of function mechanism 
as the earlier mutations.  
vi
  
  To further investigate the role of MEF2A in atherogenesis, we studied knockout 
mice targeted to the mouse Mef2a gene and created a novel Mef2a+/- Apoe-/- knockout 
mouse strain. We then analyzed diet-induced atherosclerosis and spontaneous lesion 
formation in the Mef2a and Mef2a+/- Apoe-/- mice.  A total of 39 Mef2a knockout mice, 
including 20 males (8 wild type Mef2a+/+ and 12 heterozygous Mef2a+/-) and 19 females 
(9 wild type Mef2a+/+ and 10 heterozygous Mef2a+/-) were fed on atherogenic/paigen diet 
for 38 weeks.  A total of 47 Mef2a +/+, Mef2a+/- mice on  Apoe-/-  knockout background, 
including 26 males (15 wild type and 11 heterozygous) and 21 females (9 wild type and 
12 heterozygous) were maintained on a Western-type diet for 12 weeks. The mice were 
analyzed for quantitative atherosclerosis, platelet aggregation, and vascular permeability 
to determine the role of Mef2a in the development of atherosclerosis. Our studies showed 
that in the atherosclerosis-susceptible apolipoprotein E knockout mice, Mef2a deficiency 
increased the severity of atherosclerotic lesions in the proximal aorta by two-fold (P = 
0.0003), but not in the Apoe+/+ background. Assessment of vascular permeability in 24 
Mef2a +/+, Mef2a+/-  mice on Apoe-/-  knockout background revealed that heterozygotes 
had high vascular leakage (P = 0.000012).   
  We also found that lipid levels and platelet aggregation did not contribute to the 
formation of atherosclerotic lesions in these mice. Thus, our results support the 
hypothesis that Mef2a deficiency may promote atherosclerotic lesion formation in the 
proximal aorta possibly due to increased vascular permeability.  
  Our findings have helped us to understand the role of Mef2a in the development 
of CAD and MI.  These studies will further emphasize the importance of incorporating 
Mef2a as a genetic marker to identify patients with CAD/MI.  Identification of patients 
vii
  
with CAD/MI will assist them in improving their lifestyles to prevent and manage CAD.  
Future studies on MEF2A and CAD may provide additional insights into the pathogenic 
mechanisms of CAD, which may be important for development of new therapeutic 
treatments for CAD patients.   
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     CHAPTER I 
BACKGROUND AND INTRODUCTION 
 
Coronary artery disease (CAD) and myocardial infarction (MI) 
Coronary arteries are the main blood vessels that supply blood to the heart 
muscle.  The heart is like any other organ and requires a continuous supply of oxygen and 
other nutrients in order to function. Coronary artery disease (CAD), the most common 
form of heart disease, is attributed to atherosclerotic plaque buildup in the walls of the 
epicardial coronary arteries (1,2).  The atheroma accumulation can limit the blood flow to 
the myocardium, resulting in symptoms of ischemia. In some patients, inflammation at 
the site of atheroma leads to plaque fissure, rupture, or erosion.  These events can result 
in sudden coronary thrombosis and myocardial infarction (MI) (1-3).   
CAD/MI claims more lives each year than the other five leading causes of death 
combined (cancer, respiratory diseases, accidents, diabetes mellitus, and pneumonia) 
(4,5).  It accounts for one of every 5 deaths, and overall, it is estimated to affect more 
than 13 million Americans.  Several risk factors have been identified for CAD and MI, 
including a family history, male gender, high blood cholesterol and other lipids, smoking, 
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physical inactivity, overweight and obesity, hypertension, and diabetes (6-9). A family 
history of CAD is one of the most significant risk factors for the disease.   
General features of CAD 
 Figure 1 shows general features of CAD in human coronary arteries. It explains 
plaque formation in the various branches of the arteries which include the left main 
artery, anterior descending artery, mid left circumflex, proximal circumflex artery, and 
the proximal right coronary artery; the area of the infarction of the anterior- lateral wall 
can also be seen in the heart which is affected by myocardial infarction.  
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Fig 1: Process of Atherosclerosis. (Adapted from ADAM). 
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Artery structure and function 
The molecular mechanism of CAD can be explained by understanding the 
function of the arteries. 
 
Mechanistic function of arteries (contract and relax)  
When heart contracts (systole), blood is pumped into the large arteries, such as the 
aorta and the carotid arteries which then expand. As blood flows out of these arteries into 
smaller ones throughout the body the large blood vessels then retreat back to the size they 
were prior to the heartbeat. As the arteries relax, the heart also relaxes and fills with 
blood in preparation for the next heartbeat (diastole). Thus, the large blood vessels, which 
supply blood to the head and body, expand when the heart contracts and retracts when the 
heart is filling with blood for the next heartbeat. 
 
Development of atherosclerosis 
For the past several decades, the understanding of mechanism of the pathogenesis 
of atherosclerosis has undergone a major thought change (10). A better understanding of 
the biology and the pathophysiology of atherosclerosis (CAD) is critical in gaining 
insights into the development and cause of the disease. Recent studies have provided new 
insights into the understanding of this disease. The knowledge of the structure and 
anatomy of coronary arteries will be highly useful to develop a better understanding of 
this disease process. 
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 The structure of a normal coronary artery reveals the endothelium, which is a 
mono layer of endothelial cells on the luminal side or the inner most, followed by the 
intima which consists of collagens and proteoglycans, the middle layer media is made up 
of a multilayer smooth muscle cells (SMC), which provide the structural integrity and the 
outer most layer is called the adventitia which is made up of connective tissues, 
fibroblasts and SMC (Fig 2).   
 
 
 
 
Fig 2: Structure of normal artery and its function. (Adapted from ADAM). 
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The current evidence suggests that development of atherosclerosis or CAD begins 
with inflammation of the arteries which is initiated by infiltration of lipoproteins (fats) 
and monocytes into the intima region. The function of endothelial cells (ECs) as a 
protective sheet preventing leukocyte adhesion, is disrupted during proinflammatory 
stimuli, such as high fat diet, high levels of cholesterol, obesity, hyperglycemia, insulin 
resistance, hypertension, and smoking. This activates the expression of several adhesion 
molecules such as P-selectin and vascular cell adhesion molecule-1 (VCAM-1), by the 
endothelial cells which help the transfer of lipid particles and blood monocytes to the 
endothelium through these adhesion molecules (11-13) (Fig 3). 
The lipid particles (mainly LDL’s) associate with other substances of the 
extracellular matrix in the intima, such as proteoglycans, and gradually enlarge and 
reduce the size of lumen. This isolates the lipoproteins within the intima, from plasma 
antioxidants, as the LDL’s undergo oxidative modification (14–16). Oxidatively modified 
LDL particles are made up of lipid and protein moieties, which can induce a local 
inflammatory response (17). Oxidized LDL’s are later absorbed by monocytes. 
Monocytic cells interact with human ECs and increase monocyte matrix 
metalloproteinase 9 (MMP-9) production by several folds, thereby causing gradual 
infiltration of leukocytes through the endothelial layer and its associated basement 
membrane (18). Inflamed intima releases macrophage colony stimulating factor, which 
differentiates monocytes into macrophages (19, 20). This stimulation also increases 
expression of scavenger receptors, by macrophage, which absorbs modified lipoproteins 
via receptor-mediated endocytosis.  
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Fig 3:  Initiation of atherosclerosis. (Adapted from Libby P etal   Inflammation and 
atherosclerosis. Circulation 2002;105:1135– 43 ). 
 
The diagram shows a cross-section through a muscular artery depicting a classic 
trilaminar structure. The intima of normal arteries is composed of a single layer of 
endothelial cells overlying a subendothelial matrix that contains occasional resident 
smooth muscle cells. The underlying tunica media, separated from the intima by the 
internal elastic lamina, contains multiple layers of vascular smooth muscle cells. The 
adventitia, the outermost layer of the blood vessel, separated from the media by the 
external elastic lamina, is not depicted in this diagram. Circulating leukocytes adhere 
poorly to the normal endothelium under normal conditions. When the endothelium 
becomes inflamed, however, it expresses adhesion molecules that bind cognate ligands 
on leukocytes. Selectins mediate a loose rolling interaction of leukocytes with the 
inflammatorily activated endothelial cells. Integrins mediate firm attachment. 
Chemokines expressed within atheroma provide a chemotactic stimulus to the adherent 
leukocytes, directing their diapedesis and migration into the intima, where they take 
residence and divide.  
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Further, macrophages are converted into foam cells by the accumulation of 
cholesteryl esters in the cytoplasm. Necrosis and apoptosis of foam cells lead to a 
necrotic core with a mass of cell debris and lipids.  Macrophages and foam cells secrete 
cytokines, inflammatory molecules and growth factors that facilitate SMC migration and 
proliferation and production of extracellular matrix, forming plaques with fibrous caps.  
When the plaques are stable, the patient may experience stable angina.  However, if 
plaque rupture occurs, it leads to thrombosis and the patient may experience unstable 
angina, acute myocardial infarction (MI), or sudden death (6,7). Thus making the process 
of atherosclerosis a complex disease (Fig 4). 
Cholesterol hypothesize has always played a key role in understanding the 
pathophysiology of atherosclerosis (21). For over several years’ cholesterol and LDL 
concentrations have been diagnosed as a major risk factor along with age. Researchers 
have gained extensive knowledge in understanding the importance of modified 
lipoproteins in the pathogenesis of atherosclerosis. This led to the development of several 
treatment options to patients in reducing clinical events. The overview of the 
pathophysiology of CAD and MI above represents the current prevailing mechanism for 
the pathogenesis of CAD and MI, and suggests that CAD is a disease of lipid 
metabolism, smooth muscle cell proliferation and migration, and inflammation and 
immune responses.   
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However, several other risk factors have also been identified to cause the 
inflammation in cells involved in atherosclerosis which includes, cigarette smoking, 
insulin resistance/diabetes, and hypertension (22). And recent advances in the molecular 
genetic studies have, provided new insights into the pathogenic mechanism of CAD and 
MI.   
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Fig 4:  Progression of atherosclerosis. (Adapted from Libby P etal Inflammation and 
atherosclerosis. Circulation 2002;105:1135– 43 ). 
 
Macrophages augment the expression of scavenger receptors in response to 
inflammatory mediators, transforming them into lipid-laden foam cells following the 
endocytosis of modified lipoprotein particles. Macrophage-derived foam cells drive 
lesion progression by secreting proinflammatory cytokines. T lymphocytes join 
macrophages in the intima and direct adaptive immune responses. These leukocytes, as 
well as endothelial cells, secrete additional cytokines and growth factors that promote 
the migration and proliferation of SMCs. In response to inflammatory stimulation, 
vascular SMCs express specialized enzymes that can degrade elastin and collagen, 
allowing their penetration into the expanding lesion. 
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Genes causing CAD 
CAD and MI are multi factorial disorders associated with several factors such as 
family history, male gender, high blood cholesterol and other lipids, hypertension, 
diabetes etc,. Genetic factors play an important role in development of CAD and MI.  An 
effective approach for identifying a specific gene for CAD and MI appears to be a 
genome-wide linkage scan in large, extended families with multiple affected family 
members.   
To date, several large-scale genome-wide scans using hundreds of sibpairs have 
been reported to identify chromosomal regions implicated in complex CAD or MI traits.  
Thus, CAD may be associated with multiple genes, making it a polygenic disorder. As 
CAD is a complex genetic trait, in most cases, CAD is not inherited in a clearly dominant 
or recessive manner. Instead, a person may have mutations in some genes that increase 
risk and mutations in other genes that decrease risk.  The interactions among these genes 
and environmental factors are the key to the development of CAD.   
We have recently mapped a genetic susceptibility locus for MI to chromosome 
1p34-36 region by analyzing MI as a complex trait in 428 nuclear families with 
premature CAD and MI (23). Another susceptibility locus for MI was identified by others 
in the chromosome 14q region (24).  Five CAD susceptibility loci have been identified on 
chromosome 2q21.1-22 (25), 2q36 (26), 3q13 (27), 16p13-pter (28), and Xq23-26 (25).  
The specific genes at all these loci, however, remain to be identified or cloned.   
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Table1:  List of the genes that have been identified for CAD and MI 
 
Gene  Cause Effect 
ACE( Angiotensin I-Converting 
Enzyme) 
Increased Risk for CAD CAD 
5,10-methylenetetrahydrofolate 
reductase (MTHFR) gene 
mutation 
Val was substitute for Ala CAD 
angiotensinogen gene T235 Angiotensinogen T235 
homozygotes are at significantly 
increased risk of CHD generally 
CAD and 
myocardial 
infarction 
LDLR( low-density lipoprotein 
receptor) 
Nonfunctional receptor fails to 
take up plasma cholesterol 
Familial 
hypercholesterol
emia 
APOB-100(apolipoprotein B-
100) 
Apolipoprotein B-100 fails to bind 
LDL receptor) 
Familial ligand-
effective 
apolipoprotein 
B-100 
RyR2 (ryanodine-receptor 
calcium-release channel)l 
Stress-induced calcium overload 
in myocytes may be a mechanism 
Catecholamine-
induced 
ventricular 
tachycardia 
APM1(adiponectin gene) SNP+45 T>G CAD 
MEF2A Seven-amino acid deletion, 4 
missense mutations in MEF2A 
CAD and MI 
LRP6 Missense mutation CAD 
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MEF2A, first non lipid gene for CAD and MI 
Focusing on a large CAD/MI family with autosomal dominant inheritance, we 
recently demonstrated genetic linkage of CAD/MI with a DNA polymorphism in 
chromosome 15q26 region, D15S120 (we designated this locus as adCAD1) (29).  This 
region contains 93 genes, of which there are 43 known and 50 unknown genes (Fig 5). 
Of the known genes, Mef2a is a gene that encodes a transcription factor and became a 
strong candidate due to its mRNA expression in blood vessels during mouse early 
embryogenesis (30). Expression of MEF2A protein was detected as early as day 8.5 
postcoitum in cells of embryonic vasculature, and the pattern is similar to vascular 
endothelial growth factor receptor 2 (VEGFR2) and Von Willbrand factor (both are 
endothelial cell markers) (31,32).  Although Mef2a was initially identified as a muscle-
specific gene,  later it was shown to be highly expressed in the endothelium of coronary 
arteries (29).  
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Fig 5: Mapping of adCAD/MI1 to chromosome 15. (Adapted from Wang et al 
Science,2003, 302, 1578–1581). 
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A systematic mutational screening of the entire Mef2a gene using direct DNA 
sequence analysis revealed a 21–base pair (bp) deletion in exon 11 in all ten living 
affected members in the large family (29) (Fig 6).  
The 21-bp deletion led to a deletion of seven amino acids of MEF2A (
Q440P441P442Q443P444Q445P446 or 7aa). The deletion co-segregated with CAD in the 
family and absent in 119 individuals with normal angiograms, suggesting that the deletion 
was responsible for CAD and MI in this large family. The 7-amino acid deletion of 
MEF2A is a functional mutation that disrupts the transcriptional activation activity of 
MEF2A by a dominant-negative mechanism (29). 
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Fig 6: MEF2A intragenic deletion co segregates with CAD/MI in kindred QW1576. 
(Adapted from Wang et al Science 2003, 302, 1578–1581). 
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Figure 6 shows the pedigree structure of kindred QW1576. Individuals with 
characteristic features of CAD and MI are indicated by closed squares (males) or closed 
circles (females).  Unaffected individuals are indicated by open symbols. Normal males 
under the age of 50 years or normal females under 55 years are shown with light gray 
color as uncertain phenotype.  Deceased individuals are indicated by a slash, “/”.   The 
proband is indicated by an arrow.  Each individual's ID# is shown below each symbol.  
The results of genotypic analysis are shown below each symbol: "+" indicates the 
presence of the 21-bp deletion of MEF2A (heterozygous);  "-", absence of the deletion.   
The results for DNA sequence analysis of the wild type (WT) allele and the 21-bp 
deletion allele (D21bp) of Mef2a are shown in Figure 7.  Sequence analysis of exon 11 of 
Mef2a in the proband (II.1) revealed the presence of a deletion.  The wild type and 
deletion alleles were separated by a 3% agarose gel or an SSCP (single strand 
conformation polymorphism) gel, purified and sequenced directly.  The location of 
D21bp is indicated.  
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Fig 7: MEF2A 21bp deletion sequence analysis. (Adapted from Wang et al Science 
2003, 302, 1578–1581). 
 
 
 
 
 19 
 
After this initial finding, we performed identification and functional 
characterization of three new MEF2A mutations in four families with CAD (33).  We 
discovered that all three missense mutations are loss-of-function mutations, suggesting 
that MEF2A mutations can cause CAD/MI by multiple molecular mechanisms.  These 
results strongly support the premise that MEF2A is adCAD1. Genotype-phenotype 
correlation studies suggest that individuals with the dominant negative mutation may 
display the more severe form of CAD with a high incidence of MI than those carrying 
loss-of-function mutations. We also provided preliminary data that estimated the 
frequency of MEF2A mutations in the patient population with CAD and MI.    
Later, Weng et al (34) reported the 21-bp deletion in a presumed normal 
individual, which may suggest that the penetrance of the deletion is not complete.  On the 
other hand, the individual with the 21-bp deletion was not well-characterized and Weng 
et al. also reported the identification of a new variant S360L. The control groups were not 
checked for coronary angiogram results and were tested only on the resting 
echocardiograms (35). On the other hand, our results have been replicated in a Spanish 
population showing a significant association of the P279L mutation with MI patients 
(36). 
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The MEF2 family of transcription regulatory proteins 
The MEF2 family of transcription factors (myocyte-specific enhancer factor-2) 
has been extensively studied primarily in muscle cells and has been shown to play a key 
role in myogenesis and morphogenesis of cardiac or skeletal muscle.  MEF2 proteins are 
also involved in neuronal cell survival, T-cell apoptosis, and cellular responses to growth 
factors, cytokines and environmental stressors (37-46). Recent studies, as discussed 
below, suggest that MEF2 proteins also regulate vascular morphogenesis, including 
endothelial function and development.   
The MEF2 family consists of four members, designated as MEF2A, MEF2B, 
MEF2C, and MEF2D (39,40). They are nuclear phosphoproteins belonging to the MADS 
(MCM1, agamous, deficiens, serum response factor) superfamily of DNA binding 
proteins.  The four MEF2 proteins share approximately 50% amino acid identity overall, 
but have more than 95% similarity at the N-termini. MEF2 proteins have an identical 
structure of functional domains (Fig 8). The N-termini of the MEF2 proteins contain the 
MADS domain responsible for specific DNA binding and dimerization, followed by the 
MEF2 domain that increases DNA binding and mediates interactions of MEF2 proteins 
with other cofactors. The C-termini of MEF2 factors contain the transcriptional activation 
domains, which are also the targets of MAP kinase activation pathway and intracellular 
signaling cascades activated by calcium (47-50). The C-terminal ends contain the nuclear 
localization signals of MEF2 proteins for transporting these transcription factors into the 
nucleus.   
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The MEF2 proteins bind as homo- and heterodimers to a cis-element with the 
consensus sequence (C/T)TA(A/T)4TA(G/A) in the promoter and regulatory regions of 
many cardiac and skeletal muscle-specific genes. The 3-dimensional structure of a 
complex between DNA and the core dimeric DNA binding domain of MEF2A (residues 
1-85; containing residues 1-58 for MADS domain and residues 59-73 for MEF2 domain) 
has been determined.  The MADS domain mediates recognition and specificity of DNA 
binding, and both the major and minor grooves of the DNA are involved in this 
interaction (38). MEF2 proteins have been shown to interact with many different 
cofactors, which may be a mechanism by which MEF2 factors control many different 
cellular processes.  These factors include proteins that can bind and stimulate MEF2 
activity including MyoD, GATA, NFAT, TH receptor, p300/PCAF, 14-3-3, and ERK5, 
and other proteins that suppress MEF2 function such as HDAC4, HDAC5, HDAC7, 
HDAC9, MITR, and Cabin.  The interaction of MEF2 with MyoD regulates skeletal 
muscle differentiation, and the interaction with GATA factors may be important for 
cardiovascular development.      
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        Fig 8: MEF2A structure and locations of CAD-associated mutations in MEF2A.   
The N-terminal end of the MEF2A protein contains the MADS domain responsible for 
specific DNA binding and dimerization, followed by the MEF2 domain that increases 
DNA binding and mediates interactions of MEF2 proteins with other cofactors (GATA, 
ERK5, HDAC, etc.).The C-terminal region of MEF2A contains the transcriptional 
activation domains, the C-terminal end of MEF2A contains the nuclear localization 
signal (NLS). 
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MEF2B, a distinct member in the MEF2 family 
Similar to other MEF2 members, MEF2B also binds to A/T-rich DNA sequences 
and regulates gene expression through the interactions with other co-activators and co-
repressors in several tissues.  MEF2B is the only member of MEF2 family that regulates 
smooth muscle myosin heavy chain gene expression in muscle cells (51). Whereas, in 
neuronal cells, MEF2B and MEF2C, together with adhesion related kinase (Ark), repress 
the expression of gonadotropin releasing hormone (GnRH) (52).  
 Among the MEF2 family of transcription factors in vertebrates, MEF2B is the 
most divergent member. It is significantly homologous with other MEF2 members within 
the MADS/MEF2 domains, whereas the C terminal region (transactivation domain) 
shows relatively little homology (53).  
MEF2s are in an inactive state in the presence of class II histone deacetylases 
(HDACs).  HDACs repress transcription by deacetylating core histones, which results in 
chromatin condensation. Whereas MEF2 activity is repressed by Cabin1 in T 
lymphocytes, Cabin 1 recruits class I HDAC to MEF2 target genes and thus represses 
MEF2 activity. Recent studies provide further information as to how MEF2 interacts with 
HDACs and Cabin1. Han et al solved the crystal structure of the MADS-box/MEF2 
domain of human MEF2B bound to a motif of Cabin1 and DNA (54). MEF2 domain was 
shown to be on the surface of the MADS domain stably folded and Cabin1 binds a 
hydrophobic groove on the MEF2 domain. Later studies revealed the structural 
complexity of MADS-box and MEF2 domain of MEF2B. Furthermore, the MEF2-
binding motif of class II HDAC9 was also determined which is found to be similar to the  
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structure of the Cabin1/MEF2/DNA complex (55). Thus, these studies provide a clear 
insight about the process in which MEF2 proteins recruit transcriptional co-repressor 
Cabin1 or HDACs to specific DNA sites through the MEF2 domain.   
 The functional role of MEF2B remains largely unknown. Unlike other MEF2 
members, MEF2B is not phosphorylated by p38 or BMK1. Further studies need to be 
performed to understand how MEF2B becomes phosphorylated (55,56). MEF2B binds 
with reduced affinity to the other family members which have the MEF2 consensus 
sequence, while MEF2A, -C and –D have the same DNA specificity (55, 57).  
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MEF2C, another member of the MEF2 family and its significance for the 
development of the vascular system  
 MEF2C, is highly expressed in various cell types, such as skeletal, cardiac, and 
SMC as well as the neural crest and the vascular endothelium. It plays a major role in 
vascular development and is required for cardiac myogenesis and morphogenesis (58-60). 
MEF2C null mice exhibited profound cardiac defects including a near complete loss of 
the right ventricle and its outflow tract, defective aortic arch looping, and a disorganized 
endocardium. As a result, mouse embryos lacking MEF2C failed to form a functional 
vascular system and had major defects in vasculogenesis that was lethal by embryonic 
day E9.5. Although endothelial cells were found to develop, they failed to organize into 
vascular plexus, suggesting a significant role of MEF2C in endothelial cell 
differentiation.   
 A separate study on MEF2C null mice also revealed lack of vascular formation, 
such as arrest of yolk sac capillary network and yolk sac vessel disruption (61). A 
reduced number of capillaries, and enlarged vascular lumen were observed in the head 
and those caudal to the heart, whereas the vessels located dorsally and anterior to the 
heart have smaller lumens than normal control animals. The endocardium of MEF2C null 
embryos was malformed, and the endothelial cells in this region were rounded with 
erratic orientations with respect to the underlying myocardium. This suggests that a 
defect in endothelial cell differentiation or a defect in angiogenesis occurs. Moreover, 
expression of angiopoietin 1 and VEGF was reduced in the endocardial defects, which 
indicates that MEF2C has an essential function in the myocardium to regulate the proper  
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expression of these cytokines and to direct endocardial formation.  
 BMK1 (Big MAPK-1, also called ERK5) and MEKK3 null mice (MAPK kinase 
kinase-3), members of the MAPK signaling pathway and upstream targets of MEF2C 
also have similar embryonic abnormalities. The MAPK signaling pathways start with 
activation of MEKK by G-protein-coupled receptors. Activated MEKK phosphorylates a 
subordinate MAPK kinase (e.g. MEK5), which further activates a MAPK (e.g. BMK1 or 
ERK5) by phosphorylation.BMK1 can stimulate transcriptional activation of MEF2 
factors by phosphorylating the transcription activation domains or by direct interactions 
with MEF2 factors (62-64).  
Studies with BMK1 conditional knockout mice provided direct genetic evidence 
that a BMK1-MEF2C pathway is critical for endothelial cell survival and blood vessel 
integrity (65). Removal of BMK1 protein led to the death of endothelial cells partially 
due to the deregulation of transcriptional factor MEF2C. Studies of the MEF2C have 
demonstrated that MEF2C is an early marker of the vascular development that mediates 
endothelial cell organization and angiogenesis.   
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MEF2D, the other member of MEF2 family with a key role in apoptosis 
Similar to MEF2A, MEF2D is also ubiquitously expressed. Studies on MEF2D 
reveal that it plays a significant role in T-cell receptor (TCR)-mediated apoptosis during 
thymic negative selection. MEF2D mediates calcium-dependent transcription of Nur77, 
which is also a transcription factor involved in TCR-mediated apoptosis of thymocytes 
(66, 67).  MEF2D mediated the calcium-dependent induction of Nur77 by binding to two 
calcium-responsive DNA elements in the Nur77 promoter (67). Further studies are 
needed to investigate if there is any relationship between MEF2D and vascular 
development.  
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MEF2A model of atherosclerosis 
 
   
 
Fig 9: MEF2A model of atherosclerosis 
A schematic diagram of a coronary artery.  It consists of the endothelium and intima, 
internal elastic lamina, media, and adventitia.  MEF2A is expressed in the endothelium.  
Mutations detected in this gene lead to a dysfunctional endothelial cell layer and 
culminate in the generation of atherosclerosis. 
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Based on the previous findings that mutations in MEF2A are associated with 
CAD and MI, and MEF2A is highly expressed in endothelial cells in coronary 
endothelium, we proposed that dysfunctional or abnormally-developed endothelium is a 
trigger for the development of CAD (45,48). As a transcription factor, MEF2A is 
expected to control the expression of many genes in the coronary endothelium.  
Mutations/deletions in MEF2A will alter the expression of a subset of genes and thus 
reprogram the transcriptional profile in the endothelium, leading to the abnormally 
developed or malfunctional endothelium. Thus a defective endothelium, which acts as a 
barrier between blood and artery, is now susceptible to the infiltration of inflammatory 
particles such as LDLs, monocytes, and macrophages, which ultimately leads to 
atherosclerosis .  
To test the above hypothesis and to determine the functionality of Mef2a, we 
studied the Mef2a knockout mice and also crossed Mef2a deficient mice (Mef2a +/-) with 
apolipoprotein (apo) E knockout (Apoe / ) mice which were previously shown to 
spontaneously develop atherosclerosis on a western or chow diet. We analyzed 
quantitative atherosclerosis, platelet aggregation, and vascular permeability in these 
murine models to determine the effects of the Mef2a deficiency on atherosclerosis. 
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 CHAPTER II 
               METHODS 
IDENTIFICATION OF MEF2A MUTATIONS ASSOCIATED  
WITH CAD AND MI 
Study subjects and isolation of genomic DNA  
The study participants were identified and enrolled at the Cleveland Clinic 
Foundation through the Gene Bank program at the Cleveland Clinic Heart Center, which 
is a registry of data in conjunction with a repository of DNA/serum/plasma samples for 
the individuals undergoing coronary catheterization. Family data and blood samples were 
also obtained when possible from family members if a positive mutation was identified in 
the proband.  This study was approved by the Cleveland Clinic Foundation Institutional 
Review Board on Human Subjects.   
The diagnostic criteria for CAD include: 1) any preceding or existing indication 
of MI which is based on the existence of at least two of the following: prolonged chest 
pain, ECG patterns consistent with acute MI, or significant elevation of cardiac enzymes;  
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2) percutaneous coronary angioplasty (PTCA); 3) coronary artery bypass surgery 
(CABG); or 4) coronary angiography with >70% stenosis (28). The controls were 
selected as those individuals with coronary angiography showing no luminal stenosis, and 
were ≥55 years of age. After drawing the blood from these patients, genomic DNA was 
isolated using the Mammalian DNA Isolation Kit (Roche Diagnostic Co., Indianapolis, 
IN, USA).  
Mutational analysis 
The genomic structure of the MEF2A gene was determined by comparing its 
cDNA sequence to the genomic sequence using BLAST. PCR primers were designed 
based on the flanking intronic sequences of each exon (Table 2). The complete coding 
region and the intron splice sites of the MEF2A gene were amplified by PCR. Amplified 
products were purified using the QIAquick PCR Purification Kit (QIAGEN, Valencia, 
CA) and sequenced with forward and reverse primers by an ABI3100 Genetic Analyzer 
(Applied Biosystems, Foster City, CA). 
Mutation screening of genomic DNA was carried out using single strand 
conformation polymorphism analysis (SSCP) from CAD and MI patients as well as with 
control individuals as described (68-72).   
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Table 2: PCR primers for amplification of MEF2A exons and mutational analysis. 
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SSCP method has been proved to be a very useful way of detecting mutations for 
large-scale studies. We did PCR to amplify all 11 exons of MEF2A and by use of α-32P-
dCTP in the PCR reactions. The PCR products were denatured, and separated by 
electrophoresis through a polyacrylamide gel at 4˚C. The abnormal bands were detected 
by exposing the gel to a film. After the autoradiography, the abnormal bands were cut 
and dehydrated and then re-amplified using the original PCR primers, and sequenced by 
the Big Dye Terminator cycle sequencing reaction and an ABI PRISM 3100 Genetic 
Analyzer.      
Plasmid constructs and mutagenesis 
The MEF2A expression construct was created by cloning the full-length MEF2A 
cDNA into plasmid vector pcDNA3, and was kindly provided by Dr. Eric N. Olson at 
University of Texas Southwestern Medical Center.  Each missense mutation of MEF2A 
was introduced into the wild type construct by PCR-based site-directed mutagenesis, and 
verified by DNA sequence analysis.   
The full-length GATA-1 cDNA was isolated by RT-PCR, and cloned into 
pcDNA3 (29), resulting in the GATA-1 expression construct. The reporter gene for 
transcriptional activation assays, ANFp-700/Luc, has –700 bp to +1 bp upstream region 
from the transcription start site of the human atrial natriuretic factor (ANF) gene fused to 
the luciferase gene (29).          
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Transcriptional activation (luciferase) assays 
The effect of missense mutations of MEF2A on transcriptional activation was 
analyzed using the ANFp-700/Luc reporter gene. The reporter gene was co-transfected 
into HeLa cells with either the wild type or mutant MEF2A expression construct alone or 
in combination with the GATA-1 expression construct.  Transcriptional activation activity 
was assayed with luciferase activity.   
HeLa cells were grown to 95% confluence in Dulbecco's minimum essential 
medium (DMEM) supplemented with 10% fetal bovine serum and transfected with 
Lipofectamine 2000 (Invitrogen, Carlsbad, CA) and 50 ng of DNA for the expression 
construct, 1 µg of DNA for the reporter gene, and 50 ng of internal control plasmid pSV-
galactosidase. Luciferase assays were performed using a Dual-Luciferase assay kit 
according to the manufacturer's instructions (Promega, Madison, MI). The β -
galactosidase activity expressed from pSV-galactosidase was used to normalize the 
transfection efficiency. The experiments were repeated two times in triplicate. Data are 
expressed as mean ± S.E. 
Western blot analysis   
The efficiency of transfection was examined by Western blot analysis.  Cells were 
transfected as described above, harvested, and lysed 24 h after transfection.  Forty µg of 
total cellular lysates were separated by 12% SDS-PAGE and electro-transferred to a 
polyvinylidene fluoride membrane. The membrane was probed with goat polyclonal anti-
MEF2A antiserum (Santa Cruz Biotechnology, Santa Cruz, CA) as the primary  
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antibody and the rabbit anti-goat IgG horseradish peroxidase-conjugated secondary 
antibody (Santa Cruz Biotechnology, Santa Cruz, CA).  ECL Western blotting detection 
reagents (Amersham Pharmacia Biotech) were used to visualize the protein signal.   
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DEVELOPMENT OF AN IN VIVO MOUSE MODEL FOR CAD 
Mef2a  knockout mice 
We collaborated with Dr. Eric Olson who has provided us with the Mef2a 
knockout mice. The Mef2a +/- mice have been created by Dr. Eric Olson at University of 
Texas Southwestern Medical Center (Fig 10). However, these mice were found to be 
infected with hepatitis C. Thus, our lab had these mice rederived by Jackson Lab.  We 
have received 42 Mef2a+/- mice from Jackson Lab which performed hepatitis C cleaning 
up (rederivation). These Heterozygous Mef2a+/- mice were interbred to generate Mef2a 
wild type (+/+) and homozygous mutant (-/-) mice.   
Generation of Mef2a knockout mice 
Homozygous Mef2a-/- mice are susceptible to sudden death during the first week 
of life (32) (Fig10).  The sudden death phenotype in the Mef2a-/- mice is strain-dependent 
(32).  In the mixed background, about 90% of Mef2a-/- mice die suddenly by 3 weeks of 
age, and 10% survived to 1-9 months. In the isogenic 129Sv genetic background 100% of 
Mef2a-/- mice die within the first week after the birth, while nearly 100% survived when 
mixed background 129Sv/C57B16 Mef2a-/- mice were crossed to the FVB/N background.  
No structural heart defects were detected before the death, but dilation of the right 
ventricle was detected for the homozygous Mef2a-/- mice with sudden death at necropsy. 
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Fig 10: Generation of Mef2a knockout mice (Adapted from Naya, F.J., et al, 2002 Nat. 
Med., 8,1303–1309) 
a, A diagram of the MEF2A protein is shown below the mouse Mef2a locus around exon 
2, which encodes amino acids 17−86. Homologous recombination resulted in deletion of 
coding exon 2 and insertion of a neomycin-resistance gene. B, BamHI; E, EcoRI; N, 
NheI; X, XhoI. b, PCR amplification of genomic DNA. Primers 1 and 2 (indicated in a) 
generate a 240-bp product (WT) and primers 1 and 3 produce a 380-bp product 
(Mutant). c, RT-PCR of total RNA from skeletal muscle of wild-type and Mef2a-/- mice at 
3 wk of age. A PCR fragment (240 bp) was detected in the wild-type (WT) sample 
(indicated by arrowhead to the right), but no specific PCR product was detected in the 
sample from mutant mice. Arrowhead to the left points to a nonspecific PCR product 
present in all lanes. Reactions were performed in the presence and absence of reverse 
transcriptase (RT). , wild type; , Mef2a+/-; , Mef2a-/- 
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Propagation of knockout mice deficient in Mef2a 
Mef2a+/- mice on the mixed background 129Sv/C57Bl6 were brother-sister mated 
to generate three strain-matched groups of mice, Mef2a+/+, Mef2a+/-, and Mef2a-/- in a 
1:2:1 ratio. A total of 39 mice (17 wild type and 22 heterozygous) upon weaning were 
maintained on a paigen diet or an atherogenic diet containing 1.25% cholesterol, 15% fat, 
and 0.5% cholic acid (Harlan-Teklad 88051) for 38 weeks. Aortic atherosclerotic lesions 
were quantified in Mef2a+/+, Mef2a+/  mice at this time point. Mef2a-/- mice were unable 
to survive until this time point. 
Creation of Apoe and Mef2a deficient mice 
Mef2a knockout mice were crossed with Apoe-/- mice, a widely used genetic 
model for atherosclerosis (Apoe knockout mice was kindly provided by Dr. Jonathan 
Smith from Cleveland Clinic). Although no murine model can truly simulate human 
situation, the Apoe–deficient mouse model has proved to be one of the best models to 
study the pathogenesis of atherosclerosis. In order to minimize lethality of the Mef2a-/- 
progeny, the Mef2a+/- mice in the 129Sv/C57Bl6 background were crossed to Apoe-/- 
mice on the FVB/N, yielding 50% Mef2a+/- mice that are hemizygous for Apoe. After 
mating, these progeny were crossed back to FVB/N Apoe-/- mice. We have selected 
Mef2a+/- mice that are homozygous for Apoe-deficiency (50% of the progeny). These 
mice were brother-sister mated to generate the three strain-matched groups of Apoe-
deficient mice that are Mef2a +/+, +/-, and -/- in a 1:2:1 ratios, which were used for  
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analyses (Fig 11). Littermate controls were used to decrease the potential for a 
background gene to be responsible for the phenotype.  
Both males and females were used for this study. A total of 47 mice, of which 26 
were males (15 wild type and 11 heterozygous) and 21 were females (9 wild type and 12 
heterozygous) upon weaning, were  maintained on a western-type diet containing 21% 
fat, 0.2% cholesterol, and no cholic acid (Harlan-Teklad 88137) until 16 weeks of age. 
Aortic atherosclerotic lesions were quantified in Mef2a+/+Apoe / , Mef2a+/ Apoe /  
mice at this time point. 
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      Fig11: Schematic representation for generation of Mef2a and Apoe deficient 
knockout mice. 
Step1: Mef2a knockout mice were crossed to Apoe -deficient mice.  In order to minimize 
lethality of the Mef2a -/- progeny, the Mef2a +/- mice in the 129Sv/C57Bl6 background 
were crossed to Apoe -deficient mice on the FVB/N, yielding 50% Mef2a +/- mice that are 
hemizygous for Apoe. Step2: After mating these progeny were crossed back to FVB/N 
Apoe-deficient mice, we have selected Mef2a +/- mice that are homozygous for Apoe-
deficiency (50% of the progeny).  Step 3: These mice that were brother sister mated to 
generate the three strain-matched groups of mice Apoe-deficient mice that are           
Mef2a +/+, +/-, and -/- in a 1:2:1 ratios, which were used for analyses. 
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Determination of Mef2a animal genotype 
Mice were genotyped by polymerase chain reaction (PCR) analysis. A small piece 
of mouse tail was digested in 0.4 ml lysis buffer (pH 7.5) containing (in mM) 50 Tris, 
100 EDTA, and 100 NaCl and 1% sodium dodecyl sulfate and 0.5 mg/ml proteinase K 
overnight at 55°C. After the lysis, the mixture was centrifuged (10,000 rpm/min, for 
10 min). The DNA (5 µl) sample was amplified by one sense primer (5'- GCT AGC CAA 
CAT TTC ACC TTT GAG ATC T -3' for binding to the MEF2A DNA) and two 
antisense primers (5'- CAA CGA TAT CCG AGT TCG TCC TGC TTT C -3' for normal 
sequence and 5'- GCC TTC TAG TTG CCA GCC ATC TGT TGT TTG -3' for knockout 
targeting sequence, respectively). The PCR products were separated on a 2% agarose gel 
and visualized by ethidium bromide staining. The results were analyzed as shown below.  
 
 
 
 
 
 
 
 
 42 
 
 
 
Fig 12: Genotyping of the Mef2a knockout mice. 
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Determination of Apoe animal phenotype  
The total cholesterol assay was performed to identify the Apoe-/- mice.  Briefly, 
plasma was isolated from whole blood and the biochemical assay using Stanbio 
enzymatic kit was performed. Mice with cholesterol levels of 350 mg/dl and above were 
considered to be Apoe-/- mice. 
Dietary Restrictions 
All mice were weaned at 4 weeks of age and subdivided into Mef2a knockout and 
Mef2a wild type and heterozygous on Apoe knockout background. The Mef2a knockout 
mice (n=39) were fed with the paigen diet or an atherogenic diet containing 1.25% 
cholesterol, 15% fat, and 0.5% cholic acid for 38 weeks after the weaning.  
Mef2a wild type and heterozygous on Apoe knockout background mice were fed 
with the western diet containing 21% fat, 0.2% cholesterol, and no cholic acid (Harlan-
Teklad 88137) for 12 weeks after the weaning.  The food consumption was monitored on 
regular basis. No differences in the food consumption were visible among animals of 
these two experimental groups. The animals were housed in the Cleveland Clinic Animal 
Facility in a specific pathogen-free environment in rooms with a 7 a.m. to 7 p.m. light 
dark cycle. The Cleveland Clinic Institutional Animal Care and Use Committee approved 
all procedures involving mice. 
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Blood collection and glucose measurement 
At one week before the end of the treatment period, all animals were fasted 
overnight but water was allowed to access.200-300 μl of blood was collected from all the 
mice from the orbital sinus by using micro capillary tubes with EDTA coated appendorfs. 
The peri-orbital sinus of the mouse was used as a source of venous blood. These mice 
were anesthetized using isoflurane. The main purpose of this was to study correlation 
with total and HDL cholesterol levels. Blood glucose levels were also measured in these 
animals with a single drop of whole blood with a One Touch II monitor. 
H&E staining and immunostaining 
Hearts from the Mef2a+/+, Mef2a+/- and Mef2a -/-mice were fixed in 4% zinc 
formalin. After dehydration in a graded series of ethanol, they were paraffin embedded, 
cut into serial sections at 5 µm thickness thickness (saggital sections), and subjected to 
Hemotoxylin and Eosin staining. After deparaffinization slides were placed in harris 
hematoxylin for 45 seconds followed by 1% eosin for 1 minute. Slides were then 
dehydrated in an ascending gradient of ethanol followed by xylene, and mounted in 
Cytoseal 60 (Stephens Scientific, Riverdale, NJ) for examination by light microscopy. 
Immunostaining was also performed to determine the cell layers in the coronary arteries 
and other vessels as previously described (73-75). The antibodies for CD31 (PECAM-1) 
(Sigma) and vascular smooth muscle alpha-actin (Sigma), MOMA2 (Sigma) were used as 
the markers for endothelial and smooth muscle cells, and macrophages respectively.   
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ATHEROSCLEROSIS LESION ANALYSIS  
Although there are several different assays to quantitatively assess mouse atherosclerosis 
at various locations, the aortic root assay is still considered the standard assay in many 
laboratories, as lesions start developing at this area very early this site compare to other 
areas and the aorta region is highly susceptible to atherosclerosis in mice. Other sites 
besides the aorta such as carotid, pulmonary, femoral and innominate arteries can also be 
used to locate lesions (76, 77). 
 
A detailed protocol for the assessment of mouse atherosclerosis in the aortic root is as 
follows (78): 
Materials 
1. Ketamaine/xylazine anesthesia is prepared by adding 10 ml of ketamine stock (100 
mg/ml) and 1.5 ml xylazine stock (20 mg/ml) to 35.5 ml sterile phosphate buffered saline 
(PBS). 
2. Small animal surgical tools: fine scissors, fine forceps, and coarse forceps with serrated 
tips. 
3. PBS or normal saline in a 10 ml syringe with a 24 g needle for perfusion. 
4. 10% phosphate buffered formalin (Fisher, Pittsburgh, PA. 
5. Glass Staining racks with removable trays and wire handles.  
6. Oil red-O stain (0.24%): This is prepared by combining 1 g oil red-O powder (Sigma 
Aldrich, St. Louis MO) and 250 ml 2-Propanol for 10 minutes. 150 ml of ddH20 is added 
and mixed for an additional minute, allowed to stand for 6 minutes and then filtered 
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through a 0.45 μm. Stericup (Millipore, Billerica, MA) . Oil red-O stain should be made 
freshly and used within 2 hours of preparation. 
7. Harris Hematoxylin (2.4%): 100 ml Harris Hematoxylin stock solution (Sigma 
Aldrich, St. Louis MO) is combined with 98 ml of ddH20 and 2 ml of glacial acetic 
acid and filtered. 
8. Bluing Solution: 5 drops of ammonium hydroxide reagent in 1 l of ddH20. 
9. Light Green Solution (0.25%): 50 ml of a 1% stock solution (2 g Light Green SF) 
powder (Fisher, Pittsburgh, PA), 198 ml ddH20 and 2 ml acetic acid) is added to 150 
ml ddH20.  
10. Glycerol gelatin (Sigma Aldrich, St. Louis MO). 
11. 22 x 60 mm #1 cover slips (Fisher, Pittsburgh, PA). 
12. Image Pro Plus software, packaged as Olympus Micro Suite software, Soft Imaging 
System (Lakewood, CO). 
13. Microscope equipped with video imaging camera, video capture card, and PC: 
Olympus CX41 microscope (Melville, NY), a Panasonic Industrial Color CCD Camera, 
Model #GP-KR222 (Secaucus, NJ), Pinnacle Systems video capture card and software in 
a Dell PC. 
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 Mouse sacrifice, heart removal, and fixation 
 
 
1. After the treatment period all study group mice were weighed and a 25 g mouse was 
anesthetized by intraperitoneal injection with 200 μl of the ketamine/xylazine stock, the 
volume was adjusted according to the weight of the mouse using ~8 μl of anesthesia 
stock per g body weight. Depth of anesthesia was tested by lack of response to a firm 
squeeze of the hind foot. Additional anesthesia was administered in 50 μl increments 
until this depth is achieved. The age of the mice under study should was kept constant + 
0.5 weeks, as lesion area is extremely age dependent. 
 
2. The legs of the supine mouse were taped down onto several folded paper towels, and 
the ventral surface of the mouse was wet with water or 70% ethanol (to keep the hair 
matted down). A lateral skin incision was made at the base of the abdomen extending to 
the width of the rib cage. Some skin was wrapped from the top side of the incision around 
a blunt forceps with serrated tips the mouse’s rear legs were hold down, and forcefully 
skin was torn and pulled up over the mouse’s head exposing the peritoneum and chest. 
Using a fine scissors the peritoneal membrane was cut opened from the base of the 
abdomen to the ribcage. The sternum was lifted and quickly cut with a fine forceps, and 
penetrate the diaphragm with the tip of a fine scissors. Two lateral cuts were made at the 
top of the ribcage and the ventral ribs were removed exposing the beating heart. 
 
3. The circulatory system was perfused with 10 ml of PBS or normal saline by placing 
the needle of the saline-loaded syringe into the left ventricle, using a fine scissors a cut  
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was made to the right atrium, (allowing drainage of the circulatory system into the chest 
cavity),and slowly pumping the saline into the heart. The mouse was euthanized at this 
point by exsanguination. 
 
4. The heart was gently lifted out by the apex, without squeezing the top which can 
damage the aortic root, which is completely embedded within the heart. Any fibrous 
connective tissue attached to the heart was cut, and finally the aorta was cut just above 
the level of the heart, and the heart is put into a vial containing 5 to 10 ml of 10% 
phosphate buffered formalin. The vial was placed at 40C indefinitely, until ready for 
embedding, but for a minimum of 24 hrs. 
 
 Mounting the hearts on a pedestal in OCT and sectioning hearts with a cryostat 
 
1. The lower half of the heart was removed by cutting with a razor blade. The alignment 
of this cut is crucial to getting sections perpendicular to the axis of the aortic root. The 
cut was made ~ 1mm beneath the base of and parallel to the right and left atria.  
 
2. The top half of the heart was then placed into a plastic tissue mold (lower chamber is 
1.5x 1 x 0.5 cm, L x W x D) with the cut surface at the bottom of the mold, and then 
covered in OCT compound in both the lower and upper chambers. The heart was moved 
around carefully to fill the aorta with OCT. The mold was placed in the cryostat set at -
22ºC to freeze the OCT. 
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3. The heart was removed from the base mold and mounted with the cut side facing up on 
the sample pedestal, which is mounted on the cryostat freezing stage, upon a bed of not-
yet solidified OCT. 
 
4. The pedestal was placed into the chuck of the cryostat and a 30 μm thick section was 
cut and transferred to a microscope slide for observation to check this section was parallel 
to the cut surface of the heart, or oblique yielding a partial section. More sections were 
cut with observation every ten sections to detect the atria, appearing as appendages, 
which signal the approach of the aortic sinus. The aortic sinus appears as 3 bipartite valve 
bases with attached leaflets along with an intact intima.  
 
5. Once the aortic sinus was visible, the section thickness was decreased to 10 μm and 
every other section was saved, four sections per slide covering a total distance of 80 μm. 
Six slides were prepared in this manner, covering a total distance of 400 μm, at which 
point the valve bases are shrunken, but still visible, and the valve leaflets may not all be 
visible. Slides were labeled, using a solvent resistant marker or a pencil, with the mouse 
identification number and the slide number and stored at room temp until ready to stain, 
or at -20ºC for immunostaining. 
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 Staining sections for aortic root analysis 
1. 20 slides were placed back to back in the 10 slots of each staining rack. A series of 
staining trays were set up with the solutions listed below and the slides are immersed for 
the specified times.  
2. ddH20 for 2 minutes. 
3. 60% 2-propanol for 30 seconds. 
4. Filtered oil red-O staining solution for 18 minutes, in order to stain neutral lipids. 
5. 60% 2-propanol for 30 seconds. 
6. ddH20 for 1 minute 
7. ddH20 for 1 minute 
8. Harris Hematoxylin stain for 2 minutes. 
9. Bluing solution, 10 dips. 
10. ddH20 rinse for 1 minute. 
11. Light Green counterstain for 30 seconds. 
12. ddH20 for 1 to 15 minutes to partially destain Light Green. 
13. Air dry slides until ready for cover slipping. 
14. For cover slipping, glycerol gelatin was heated to 55ºC in a water bath. One drop was 
placed over each of the 4 sections on the slide. The cover slip was placed on the slide and 
pressed down firmly to remove any air bubbles. After the glycerol gelatin sets for an 
hour, excess was removed by washing the slides in soapy water.  
 
 
 
 
 
 51 
 
Quantification of aortic root lesion area 
 
1. The slide was observed microscopically under bright field illumination using a 4x or 
10x objective lens. Video images were captured with a video capture card and frame 
grabber software 
 
2. One section on each of the six slides was quantified. Lesions consist of oil red-O 
staining lipid-filled regions as well as any fibrous regions lumenal to the internal elastic 
lamina. Using Image Pro or other similar software, and after calibration with a stage 
micrometer (for each objective lens), the lesions were circled and the area of each lesion 
for the quantified section on the slide was exported to a spreadsheet in μm2. This was 
repeated for each of the five remaining slides from the heart, using 80 μm intervals 
between the sections, if possible. 
 
3. The sum of the lesion areas were calculated for each of the six quantified sections. 
Then the mean lesion area was calculated for all of the six quantified sections. 
 
Plasma lipid analysis 
   Mice were on a 12 week western diet and were 16 weeks old.  These mice were 
fasted overnight.  200-300 µl of blood was extracted through the retro orbital sinus and 
blood was immediately spun down for 10 min at 4oC and plasma was separated .Total 
cholesterol, HDL cholesterol, and triglycerides were measured by quantitative –
enzymatic colorimetric determination Stanbio kits with the plasma isolated as described 
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above. VLDL/LDL cholesterol was deduced by subtracting HDL cholesterol from total 
cholesterol. 
 
In vivo vascular permeability assay 
We performed this assay using Evans blue dye (30mg/kg in 100 µl PBS; Sigma) 
as described previously (79). Briefly, permeability was stimulated using mustard oil 
(Sigma) and after 30 minutes, mice were euthanized and ears were removed and weighed. 
Evans blue dye was extracted, measured spectrophotometrically at 560 nm and the 
leakage was expressed as nanograms of dye per milligram of tissue. 
 
Statistical analysis 
For each mouse, the mean aortic root lesion area in μm2 was used as the primary 
measurement.  Lesion areas varied among individual mice of the same age, gender, and 
genetic background. Gender had an effect on lesion area, and females of most strains had 
larger aortic lesions than males. 
 Data are expressed as mean±SE. An unpaired Student t test was used to detect 
significant differences when two groups were compared. P values less than 0.05 were 
considered statistically significant. 
 
 
 
 53 
 
 
 
 
 
CHAPTER III 
RESULTS 
Identification of three novel MEF2A mutations associated with CAD 
The genomic structure of MEF2A and the PCR primers for successfully 
amplifying all 11 exons of MEF2A for mutational analysis were previously reported (29).  
Single-strand conformation polymorphism (SSCP) and DNA sequence analyses were 
used to screen for mutations in MEF2A. 207 independent patients with unequivocal 
diagnosis of CAD based on cardiac angiography and/or development of MI, and 191 
controls were screened (Table 3).  Patients with onset of CAD ≤55 years of age in males, 
and ≤60 years of age in females were selected.  The control individuals were individuals 
with coronary angiography documenting lack of any significant coronary arterial 
narrowing.   
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The CAD cases and controls were matched for ethnicity, age, and body mass 
index (p>0.05, Table 3). The CAD population has significant higher rates of males and 
individuals with a history of diabetes, hypertension, and smoking (p <0.01, Table 3), all 
of which are established risk factors for CAD. 
The entire coding region of MEF2A and the intron-exon boundaries were 
screened for mutations in the 207 patients and 191 controls. MEF2A mutations were 
identified in four Caucasians among the 207 CAD patients (33, Figs. 13-15 and Table 3), 
accounting for 1.93% of this patient population.  No mutations were identified in 191 
controls. MEF2A mutations identified in this study were clustered in exon 7 which 
encodes portion of a transcription activation domain of this transcription factor (31).  
After the mutation was identified, a significant effort was made to characterize family 
members, albeit with limited success.   
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Table 3: Characteristics of the study population 
  
1An unpaired t-test was used for the continuous factors (age and body mass index). 2A chi-square 
test was used for the categorical factor 
Characteristic CAD Cases 
Normal 
Controls 
P value 
Sample Size 
207 191 - 
Mean current age (SD) 
(years) 44.8 (4.8) 43.9 (7.8) 
 
0.181 
Mean Body mass index (SD) 
(kg/m2) 
31.0 (6.8) 30.6 (8.4) 0.601 
Race 
Caucasian 
African-American 
Native American 
Asian 
 
77.8% 
17.9% 
2.9% 
1.5% 
 
74.4% 
19.4% 
5.2% 
1.1% 
 
0.632 
% male 77.3 49.2 <0.0012 
% Hypertension 69.6 38.2 <0.0012 
% Diabetes 27.5 8.4 <0.0012 
% current smokers 31.9 19.4 0.0042 
Qualifying events    
Angiogram >70% stenosis 77.8 0  <0.0012 
Coronary artery bypass graft 
(CABG) 40.1 0 
 
<0.0012 
Myocardial infarction 17.9 0 <0.0012 
Angioplasty (PTCA) 40.5 0 <0.0012 
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        N263S mutation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 13: Identification of MEF2A mutation N263S in CAD patients  
GB04146, GB05072. 
(A)  Results of SSCP analysis showing an aberrant SSCP conformer (indicated by an arrow).     
N, normal control. (B)  Sequence analysis of the normal (WT) and aberrant SSCP conformers 
revealed an A to G substitution at codon 263 in exon 7 of MEF2A. This mutation causes 
substitution of amino acid residue asparagines by serine (C).   
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The MEF2A mutation N263S (change of amino acid asparagines to serine) was 
identified in two independent patients, GB04146 and GB05072 (Fig. 13 and Tables 4, 5).  
GB04146 is a 49 year old male patient who was diagnosed with CAD at the age of 41 
years, and had coronary artery bypass grafting. His risk factors include history of 
occasional tobacco use.  GB05072 is a 47 year old male who was diagnosed with CAD at 
the age of 45 years.  A stent was placed in the right coronary artery (RCA) at that time.  
In 2003, the patient had a coronary procedure with a cutting balloon, brachytherapy, and 
2 stents placed to the mid-RCA. Risk factors include hyperlipidemia (Table 5), 
hypertension with age of onset at 30 years, and history of smoking 1 pack per day for 17 
years (Table 4).  Family history includes a father who died of a massive MI at age 38.     
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        P279L mutation 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 14:  Identification of MEF2A mutation P279L in CAD patient GB00305. 
 A)  Results of SSCP analysis showing an aberrant SSCP conformer (indicated by an arrow).     
N, normal control. (B)  Sequence analysis of the normal (WT) and aberrant SSCP conformers 
revealed a C to T substitution at codon 279 in exon 7 of MEF2A. This mutation causes 
substitution of amino acid residue proline by leucine (C). 
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Mutation P279L (change of amino acid residue proline to leucine) was identified 
in patient GB00305 (Fig. 14). The patient is a 39 year male with history of CAD 
(diagnosed at 36), and a stent was placed to the proximal LAD and balloon angioplasty 
was performed in the first diagonal artery in 2001. In 2002, the patient had a coronary 
procedure with unsuccessful attempt to cross a proximal total occlusion in the RCA.  
Risk factors include dyslipidemia (triglycerides level of 252 mg/dL), history of diabetes 
mellitus, and history of 1 pack per day smoking with cessation in 2001 (Tables 4-5).  
Further analysis of family members revealed that the 66 year father of the patient also 
carried the mutation and had a clear diagnosis of CAD. The father was diagnosed with 
CAD in 2001 and had coronary artery bypass grafting. Other risk factors include 
hyperlipidemia, hypertension, obesity, diet controlled diabetes, and a remote history of 
smoking.     
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          G283D mutation 
 
 
 
 
 
 
 
 
 
 
 
Fig15:  Identification of MEF2A mutation G283D in CAD patient GB04583. 
A)  Results of SSCP analysis showing an aberrant SSCP conformer (indicated by an 
arrow). N, normal control (B) Sequence analysis of the normal (WT) and aberrant SSCP 
conformers revealed a G to A substitution at codon 283 in exon 7 of MEF2A.This 
mutation causes substitution of amino acid residue glycine by aspartic acid (C).   
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Mutation G283D (change of amino acid residue glycine to aspartic acid) was 
identified in patient GB04583 (Fig. 15). This patient is a 50 year old female with history 
of CAD first diagnosed in 2002 after a catheterization revealed left main trunk disease 
with 70-80% stenosis. The patient had coronary artery bypass grafting. Risk factors 
include hypertension and hyperlipidemia (Tables 4-5). The patient additionally was 
treated for carotid artery disease with right internal carotid endarterectomy in 2000.  
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Table 4: Demographics of the patients 
 
 
*PTCA, percutaneous coronary angioplasty; CABG, coronary artery bypass surgery; HL, 
hyperlipidemia; HTN, hypertension; DB, diabetes; S, smoking; FH, family history; OB, obesity  
 
 
 
 
 
 
 
Individual ID MEF2A 
Mutation 
Current Age Age at 
Diagnosis  
Clinical 
Diagnosis for 
CAD*  
Risk 
Factors* 
GB04146 N263S 49 41 CABG 
Angina class IV 
HL, SM  
GB05072 N263S 47 45 PTCA/stent HL, HTN, 
SM, FH 
GB00305 P279L 39 36 PTCA/stent HL, DB, SM  
CAD669 P279L 66 63 CABG HL, HTN, 
OB, DB, SM 
GB04583 G283D 50 48 CABG 
Angina class IV 
70-80% stenosis 
HL, HTN, 
SM 
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Table 5: Lipid Profile of MEF2A mutation carrier 
 
*Lipid levels in mg/dL; Cho, cholesterol; Tri, triglycerides; HDL, high-density lipoprotein; LDL, 
low-density lipoprotein. Normal Cho, Tri, HDL, LDL levels are <200, <150, >45, and <130, 
respectively. N/A 
 
Individual  
ID 
MEF2A 
Mutation 
Lipid Level* 
Before 
Medication*  
Treatment 
(medication)  
Lipid Level* After 
Medication 
GB04146 N263S Cho, 177 
Tri, 54 
HDL, 40 
LDL, 126 
Fluvastatin 
(Welchol) 
Cho, 160 
Tri, 116 
HDL, 33 
LDL, 110 
GB05072 N263S Cho, 280 
Tri, 515 
HDL, 39 
LDL, 164 
Atorvastatin 
(Lipitor) 
Cho, 148 
Tri, 340 
HDL, 31 
LDL, 49 
GB00305 P279L Cho, 182 
Tri, 252 
HDL, 27 
LDL, 130 
Simvastatin 
(Zocor) 
Cho, 167 
Tri, 134 
HDL, 30 
LDL, 110 
CAD669 P279L N/A N/A N/A 
GB04583 G283D Cho, 274 
Tri, 107 
HDL, 71 
LDL, 182 
Atorvastatin 
(Lipitor) 
Cho, 165 
Tri, 93 
HDL, 61 
LDL, 85 
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Functional defects of MEF2A missense mutations in transcriptional activation  
As all three MEF2A missense mutations identified in this study, N263S, P279L, 
and G283D, are located close to or within the transcription activation domain (amino 
acids 274-373) (31), we assessed the functional effect of these mutations on 
transcriptional activation using a reporter gene (ANFp700/Luc, Fig. 16A). The reporter 
gene has the ANF promoter (region from –700 bp to + 1bp) fused to the luciferase gene 
(29). The ANFp700/Luc reporter gene was co-transfected with wild type or various 
mutant MEF2A expression constructs into HeLa cells. Western blot analysis showed that 
both wild type and all mutant MEF2A proteins were successfully expressed in transfected 
cells (Fig. 16B). Transcriptional activity was examined and expressed as relative 
luciferase units. As shown in Fig. 16B, expression of wild type MEF2A activated 
transcription of the ANF promoter.  Mutations N263S, P279L, and G283D significantly 
reduced transcription activation by MEF2A.  Transcription activation activity in cells co-
transfected with wild type MEF2A plus each mutant MEF2A was indistinguishable from 
those transfected with wild type MEF2A alone (data not shown). These data indicate that 
mutant N263S, P279L, and G283D MEF2A proteins did not form functional 
transcriptional factors, and did not cause dominant-negative suppression of wild type 
MEF2A function. Thus, patients with the missense mutations are expected to express half 
of the normal amount of functional MEF2A.    
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We previously showed that MEF2A alone can activate transcription of its target 
genes, but in the presence of transcription factor GATA-1, synergy in transcriptional 
activation by these two proteins was observed (29). Accordingly, we then investigated 
whether the missense mutations in MEF2A could disrupt the synergistic transactivation 
between MEF2A and GATA-1. As shown in Fig. 16 C, either wild type MEF2A or 
GATA-1 alone activated expression of the ANF promoter, but co-transfection of MEF2A 
and GATA-1 into HeLa cells showed synergistic activation of the ANF promoter.  
However, mutations N263S, P279L, and G283D significantly reduced synergistic 
transcription activation by MEF2A and GATA-1.   
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Fig 16: Functional defects of MEF2A missense mutations in transcriptional activation.  
 (A) Structure of MEF2A protein with CAD/MI-associated mutations indicated.  The MEF2A 
gene consists of 11 exons and encodes a 507 amino acid protein.  The MADS domain and MEF2 
domain at the N-terminus are responsible for DNA binding, dimerization, and interaction with 
other transcription factors.  The transcription activation domain is located in the middle portion, 
and the C-terminus is responsible for nuclear localization site (NLS).(B) The effect of missense 
mutations of MEF2A on transcription activation activity in the presence (+) or absence (-) of 
GATA-1.  Transcriptional activity is shown as relative luciferase activity on the y-axis. The 
transcriptional activity for the vector alone was set arbitrarily to 1. WT, wild type.  Inset:  
Western blot analysis to determine whether mutant MEF2A was successfully expressed in 
transfected HeLa cells. C, empty vector control; WT, lane with lysate from HeLa cells containing 
expressed wild type MEF2A; N263S, P279L, G283D, lanes with lysates from HeLa cells 
containing expressed MEF2A proteins with corresponding mutations.   
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Identification of T215A MEF2A mutation associated with CAD  
After the initial studies of mutational screening of 207 patients, we screened 
another set of 200 CAD and MI patients using single stranded conformation 
polymorphism analysis as described earlier. This screening revealed another mutation in 
exon 6 of the MEF2A gene. The mutation causes a change of amino acid from threonine 
to alanine (T215A).  
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       T215A mutation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig17:  Identification of MEF2A mutation T215A in CAD patient GB04583. 
A)  Results of SSCP analysis showing an aberrant SSCP conformer (indicated by an 
arrow).  N, normal control. (B)  Sequence analysis of the normal (WT) and aberrant 
SSCP conformers revealed an A to G substitution at codon 215 in exon 6 of MEF2A.  
This mutation causes substitution of amino acid residue threonine by alanine (C). 
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 Functional defect of the T215A missense mutation in transcriptional activation 
MEF2A mutation T215A is also  located close to or within the transcription 
activation domain (amino acids 274-373) (31). We assessed the functional effect of this 
mutation on transcriptional activation using a reporter gene (ANFp700/Luc, Fig. 18A) as 
described earlier. Transcriptional activity was examined and expressed as relative 
luciferase units. As shown in Fig. 18B, expression of wild type MEF2A activated 
transcription of the ANF promoter. The T215A mutation significantly reduced 
transcriptional activation by MEF2A. Transcription activation activity in cells co-
transfected with wild type MEF2A plus the mutant MEF2A was indistinguishable from 
that transfected with wild type MEF2A alone (data not shown).  This data indicates that 
mutant T215A MEF2A protein did not form a functional transcription factor, and did not 
cause dominant-negative suppression of wild type MEF2A function. Thus, the patient 
with the missense mutation is expected to express half of the normal amount of functional 
MEF2A. Furthermore, the T215A mutation significantly reduced synergistic transcription 
activation by MEF2A and GATA-1 (Fig 18).   
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Fig18:  Functional defect of T215A missense mutation in transcriptional activation. 
 (A) Structure of MEF2A protein with CAD/MI-associated mutations indicated.  (B) The effect of 
missense mutation of MEF2A on transcription activation activity in the presence (+) or absence 
(-) of GATA-1.  Transcriptional activity is shown as relative luciferase activity on the y-axis.  
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 Characterization of Mef2a knockout mice for phenotype relevant to CAD and MI 
by atherosclerotic lesion analysis  
The Mef2a mutations identified in a large family and also in the sporadic patients 
suggest that Mef2a can play a very significant role in the pathogenesis of CAD. To 
further validate this finding, we characterized Mef2a knockout mice.  
We examined the atherosclerotic lesions in the Mef2a +/+ and +/- mice. A total of 
39 mice, including 20 males (8 wild type and 12 heterozygous) and 19 females (9 wild 
type and 10 heterozygous) were fed on paigen diet for 38 weeks. 250-300 µl of blood was 
drawn after overnight fasting through retro orbital sinus for lipid profile analysis. Whole 
blood was also used before and after fasting to measure the glucose level. The mice were 
also weighed to study for any growth defects. The heart containing the aortic root was 
fixed in phosphate-buffered zinc formalin and examined for atherosclerotic lesions in 
cross sections of the aortic root stained with oil Red O (1.8% oil red O, wt/vol, in 60% 
isopropanol, filtered twice through a 0.2-µm filter) (77,78). Atherosclerotic lesions were 
compared among these mice per genotype per gender to study lesions, Of the 39 mice, 35 
did not show any lesions. However, 3 heterozygous mice showed lesions with an average 
of 3095.33 µm2 and 1 wild type showed a lesion size of 2005 µm2 (P > 0.05, data not 
shown). 
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Increased atherosclerosis in Mef2a heterozygous mice deficient in Apoe fed on 
western diet  
 The Apoe deficient mice have been proved to be one of the best models to study 
the pathogenesis of atherosclerosis and the Mef2a and Apoe double knockout mice helped 
us determine if Mef2a defects can worsen the atherosclerosis phenotype under the Apoe 
knockout background.   
Quantitative atherosclerosis and lesion morphology 
A total of 47 mice, including 26 males (15 wild type and 11 heterozygous) and 21 
females (9 wild type and 12 heterozygous) upon weaning, were  maintained on a 
Western-type diet containing 21% fat, 0.2% cholesterol, and no cholic acid (Harlan-
Teklad 88137) until 16 weeks of age.  250-300 µl of blood was isolated after an overnight 
fasting through retro orbital sinus for obtaining plasma. The plasma was used to 
determine total and HDL cholesterol and other lipid parameters as described (80,81). 
Whole blood was also used before and after fasting to measure the glucose level. These 
mice were also weighed to study for any growth defects. These mice were then 
anesthetized and sacrificed, and the heart containing the aortic root was fixed in 
phosphate-buffered zinc formalin and examined for atherosclerotic lesions. Quantitative 
atherosclerosis assays were performed to these mice as mentioned above.  
Total  aortic lesion area was  about twofold greater in Mef2a+/ Apoe /  mice than 
in Mef2a+/+Apoe /  controls (Fig. 19A and 19B). Aortic lesions in all groups were 
observed in the proximal aorta. The lesions were increased by two fold in the 
heterozygotes  (P ≤ 0.0003). The average size of lesions observed in the wild type males 
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and females was 46621 µm2 and 61568 µm2, respectively and in the heterozygous males 
and females was 83408 µm2 and 137822 µm2, respectively. Thus there was a two fold 
increase of the lesion sizes among the heterozygous mice compared to controls              
(P ≤ 0.0003).  
Compared with Mef2a+/+Apoe /  controls, Mef2a+/ Apoe /  males had 78% 
larger lesions (P = 0.0003). Compared to the Mef2a+/+Apoe /  controls, Mef2a+/ Apoe /  
females had 123% larger lesions (P = 0.0003). 
In a subset of mice, we examined the morphology of the aortic root lesions. 
Lesions of Mef2a+/ Apoe /  mice consistently appeared more complex than those of   
Mef2a+/+Apoe /  controls, with more area occupied by necrotic core and cholesterol 
crystals and some lesions having fibrous caps (Fig. 20).  
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Fig 19 A: Atherosclerotic lesion analysis in Mef2a+/+, Mef2a +/- male mice on Apoe  
knockout background. 
A total of 26 Males were maintained on western diet for 12 weeks. They consisted of 15 
wild type  and 11 heterozygous mice .The average size of lesions observed in the wild type 
males were  46621 µm
2 
 and 83408 µm
2 
 in  the heterozygous males  (P= 0.00037).  
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Fig 19 B: Atherosclerotic lesion analysis in Mef2a+/+, Mef2a +/- female mice on Apoe  
knockout background. 
A total of 21 females were maintained on western diet for 12 weeks. They included  9 wild 
type  and 12 heterozygous mice.  The lesions were increased by more than two fold in the 
heterozygous mice compared to wild type control mice (P =  0.0003).  The average size 
of lesions observed in the wild type were 61568 µm2 and 137822 µm2 in the heterozygous 
mice. 
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Fig 20: Morphology of aortic lesions from proximal aortic roots. 
 
Representative section from the aortic root showing lesions in Mef2a+/+Apoe-/- mouse at 
low- (X4)(A) and high- magnification detail of lower right profile in A (X20).(B) 
Representative section at the aortic root lesion from Mef2a+/-Apoe-/- mouse at low-(X4) 
(C) and high-magnification detail of lower right profile in C (X20). (D) Lesions in 
Mef2a+/-Apoe-/- mice show more complex features, which include several sharp circular 
lucencies indicative of cholesterol crystals and necrotic core. 
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The graphs in Fig 19A and B represent the lesion sizes in both male and female 
mice used in this study. The graphical representations of lesions of the wild type are seen 
on the left side and the heterozygous mice can be seen on the right. These studies show a 
significant two fold increase of the lesions in the heterozygous mice. 
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Plasma lipid levels 
To establish that the differences in atherosclerotic lesion development did not 
result from differences in plasma levels of cholesterol or other lipid parameters, we 
measured total cholesterol, high density lipoprotein cholesterol (HDL-C), very low 
density lipoprotein cholesterol (VLDL-C), triglycerides (TG) in the plasma. Total plasma 
cholesterol levels were similar in mice of all genotypes (Table 6), as were HDL-C, 
VLDL-C  levels and TG (22.7 ± 4.6 vs. 24.8 ± 6.3 mg/dl for Mef2a+/+Apoe /  and 
Mef2a+/ Apoe /  mice, respectively). In addition, whole blood was also used before and 
after fasting to measure the glucose level. These mice were also weighed to study for any 
growth defects. However, no significant difference was observed between the genotypes.  
Thus the high lipid profile results among the wild type and heterozygous mice 
(Table 6) suggests, the development of atherosclerosis is due to genetic effect but not due 
to increase levels of lipid profile. 
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Table 6:  Lipid profile analysis 
 
Lipid parameters (n=22)  Mef2a+/+ Apoe -/-                              Mef2a+/- Apoe -/-             P value 
Total cholesterol (mg/dl)         567.6 ± 158.6                         517.4 ± 140.3                  0.44 
HDL-cholesterol (mg/dl)  22.7 ± 4.6   24.8 ± 6.3      0.40      
  
VLDL/LDL (mg/dl)  544.8 ± 156.2   493.01 ± 140.54     0.42 
 
Triglycerides (mg/dl)  237.9 ± 24.57   253.4 ± 23.2      0.14 
 
Glucose (mg/dl)        Fast        104.8 ± 21.9       Fast              106.25 ± 20.7                  0.87 
(Whole blood)           Fed        179.9 ± 119        Fed               175.3 ± 82                       0.92  
 
Data is presented as mean ± SD. Plasma cholesterol, HDL, VLDL/LDL, triglycerides and 
glucose levels were measured one week before the mice were sacrificed for 
atherosclerotic lesion studies. Mice were on a 12 week western diet and were 16 weeks 
old. These mice were fasted overnight.200-300µl of blood was extracted through the 
retro orbital sinus and blood was immediately spun down for 10 min at 4oC and plasma 
was separated.  Whole blood was used for glucose measurements at both fast and fed 
stage.  
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Vasculature in Mef2a+/- Apoe-/- mice is leaky 
In vivo vascular permeability assay 
In order to study the mechanism of atherosclerosis in our mice, we performed in 
vivo vascular permeability assay (Miles Assay) using Evan’s blue dye. This assay was 
done on 24 Mef2a+/+Apoe / , Mef2a+/ Apoe /   mice, including 12 wild type and 12 
heterozygous mice, kept on western diet after weaning for 12 weeks. All mice were age 
matched and gender matched. Notably, the permeability of preexisting blood vessels in 
response to a proinflammatory stimulus (with mustard oil) was 3.2 fold higher in the 
Mef2a+/ Apoe /   mice compared to the wild type mice (P = 0.000012) (Fig.21, 22).  
This suggests that the Mef2a+/ Apoe /   endothelium junctions are leaky and are 
more permeable to the influx of proinflammatory particles, leading to the development of 
atherosclerosis. 
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                                 Fig 21: In vivo vascular permeability assay. 
 
A total of 24 mice (12 wild type and 12 heterozygous) were kept on 12 weeks western diet 
and assessed for Vascular defects. Miles assay was performed by injecting Evans blue 
dye. Dye leakage can be seen in the heterozygous mouse ear tissues. 
 
Number: 1, 3, 5, 8, 10, 11, 12, 14, 17, 18, 19, 20 –Mef2a +/- Apoe-/- Mice (heterozygous) 
Number: 2, 4, 6, 7, 9, 13, 15, 16, 21, 22, 23, 24 – Mef2a +/+Apoe-/-    Mice (wild type) 
 
A: Stimulated with Mustard Oil; B: Unstimulated  
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                                    Fig 22: In vivo vascular permeability assay. 
Plasma leakage in ear skin assessed by Evans blue extravasation after treatment with 
mustard oil, with no difference in control (unstimulated ears) 
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                                                           CHAPTER IV 
 DISCUSSION AND FUTURE INVESTIGATIONS 
 Previously, we studied a large family with CAD and MI, and mapped a genetic 
locus for autosomal dominant form of CAD to chromosome 15q26 (adCAD1) (29).  
Further studies identified a 7-amio acid deletion (∆7aa) in the myocyte enhancer factor 
2A (MEF2A) that is responsible for the disease in the family (29). In this study, we 
identified three new mutations in MEF2A in four families with CAD.  These mutations 
include N263S in two independent CAD patients, P279L in a family and G283D in a 
single patient.  These three MEF2A mutations were not identified through SSCP in 200 
control individuals with normal angiograms (lack of any significant coronary arterial 
narrowings).  Functional studies indicate that all three mutations significantly reduce the 
transcription activation activity, suggesting that they are associated with CAD. We 
conclude that mutations in MEF2A cause CAD.   
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 The pathophysiology of chromosome 15-linked CAD is related to the 
deregulation of transcription programs by MEF2A in coronary arteries. We have detected 
high levels of MEF2A protein expression in human coronary arteries by Western blot 
analysis (S Arckacki and Q Wang, data not shown). Our immunostaining experiment also 
demonstrated the co-localization of MEF2A protein signal with endothelial cell marker 
CD31 signal in coronary arteries (29). These results suggest that MEF2A protein is 
expressed at significant levels in the endothelium, a single layer of endothelial cells that 
act as a barrier between the blood and coronary vessels. The detailed molecular 
mechanism of the development of CAD and MI associated with chromosome 15-linked 
CAD is uncertain. If CAD-associated mutations in MEF2A cause dysfunctional or 
abnormally-developed endothelium, the coronary vessels could be prone to inflammation 
and thrombosis, ultimately leading to development of CAD or MI.   
 Chromosome 15-linked CAD/MI results from multiple molecular mechanisms 
that reduce the transcriptional activity of MEF2A.  Coexpression of mutant and wild type 
MEF2A led to loss or dominant suppression of MEF2A transcription function. The ∆7aa 
mutation, reported previously (29), acts by a dominant-negative mechanism, whereas the 
three mutations identified in this study (N263S, P279L, G283D) act by a loss-of-function 
mechanism.  Similar findings of the spectrum of functional effects by disease-causing 
mutations has been reported in other cardiovascular diseases, including Holt-Oram 
syndrome (74,75) and long QT syndrome (LQTS) (82,83).  Sanguinetti et al. found that 
LQTS-causing mutations ∆bp1261 and ∆I500-F508 of HERG act by a loss-of-function 
mechanism, but mutations G628S and A561V act by a dominant-negative mechanism 
(84).   
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 Some LQTS-causing mutations in the LQT1 gene KCNQ1, A341V, R190Q, or 
G189R did not affect the function of wild type KCNQ1 (loss of function) (85). The other 
mutations, A177P, V254M, L272F, T311I, G306R, A341E, G345E, resulted in dominant 
negative suppression of KCNQ1 function (85,86).  No clear correlation was identified 
between the degree of HERG or KCNQ1 dysfunction and the clinical outcome.  
Interestingly, a difference in pattern of the clinical features was observed between 
MEF2A gene carriers with a dominant negative mutation and those with a loss-of-
function mutation.  The carriers with the ∆7aa mutation appear to have a more severe 
form of CAD than those with the three missense mutations.  Nine of the 13 carriers with 
the ∆7aa mutation developed MI, however, none of the five carriers with missense 
mutations developed MI (Table 3).   
 The frequency of MEF2A mutations in the CAD population is unknown.  This 
study offers a preliminary estimate.  Identification of four mutation carriers among 200 
independent CAD patients suggest that as many as 2% of CAD population may carry a 
MEF2A mutation.  These numbers need to be viewed as preliminary since the sample 
size is small and we limited our studies to affected male patients of <55 years and 
females of <60 years of age, characteristics of premature coronary artery disease.  More 
studies with large sample sizes are now needed.   
 In order to further establish the association between MEF2A mutations and 
CAD/MI, we carried out another study with additional 200 patients.  We identified one 
new mutation in exon 6 of the MEF2A gene in a CAD patient, which causes a change of 
amino acid from threonine (T) to alanine (A) at codon 215 (T215A).  
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 The functional studies on this mutation using the luciferase assay revealed that the 
mutation reduced transcriptional activity of MEF2A and acted by a loss of function 
mechanism.  The result provides further support that mutations in MEF2A are associated 
with CAD/MI.   
Atherosclerosis is a multi factorial disorder and caused by various factors such as 
family history, diet, smoking, obesity, environmental factors etc., which makes it a 
complex disease. Progressive cellular changes are seen for decades before the acute 
manifestation of cardiovascular disease. The complexity and chronocity of disease 
process, and the difficulty to distinguish lesions in an effected patient due to the 
shortcomings of diagnostic tools makes it even harder to understand the underlying 
mechanism of atherogenesis. Therefore, an alternative approach developed to study this 
disease is the use of animal models, which are now extensively used to define 
mechanistic pathways.  
Over the last decade, the mouse has become the predominant species used to 
create models of atherosclerosis due to the following reasons: 1) There is a great diversity 
of inbred strains with a clear genetic backgrounds which helps to link the genes to the 
development of the disease; 2) The recent advances in the genetic engineering has made 
it easier to modify genes in the mice by either over or under expressing specific genes, 
and creating knockout, conditional knockout, double knockout models has facilitated the 
definition of pathways in the atherogenic process.   
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Most of the mouse models such as apolipoprotein E (Apoe) and LDL receptor 
knockout mice are based on perturbations of lipoprotein metabolism through dietary 
and/or genetic manipulations.  
Although hyperlipidemia is necessary for the development of atherosclerosis, 
mouse models have demonstrated that many non-lipid factors can influence the severity 
and characteristics of lesions (77). Our work highlights a novel double knockout mouse 
model developed by crossing Mef2a and Apoe knockout mice. 
Our study examines the effect of Mef2a deficiency on atherogenesis as a single 
modifying factor. Our results indicate that Mef2a deficiency promotes lesion formation in 
the proximal aorta in the setting of increased susceptibility to atherosclerosis. The 
increase in atherosclerotic lesion area in aortas was significant (increased by 78-123% in 
Mef2a+/- Apoe-/- -deficient mice), and similarly, atherosclerosis has been reported in 
humans with Mef2a gene defects (29, 33).  
This study was carried out to investigate our hypothesis that defects in Mef2a by 
itself or defects in Mef2a under a susceptible background setting such as Apoe can lead to 
the development of atherosclerosis. This study was carried out on 39 Mef2a knockout 
mice and 47 Mef2a, Apoe double knockout mice. These two different groups of mice 
were maintained on atherogenic diet for 38 weeks and on Western diet for 12 weeks. At 
the end of the study, several parameters were measured before the mice were used for 
quantitative atherosclerosis analysis.  
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These parameters include lipid profile analysis, glucose measurements both in the 
fed and fast stage, body weight measurements and also platelet aggregation assay. These 
were done to understand if there was any correlation between the lipid levels or the 
glucose levels to the lesions that were seen. We did not find any correlation between 
these parameters, which suggest that the development of atherosclerosis observed in our 
study mice was not related to abnormal lipid profile.  
Of the 39 Mef2a knockout mice that were maintained under atherogenic diet, 35 
did not show any lesions. However, 3 heterozygous mice showed lesions with an average 
of 3095.33 µm2 and 1 wild type showed a lesion size of 2005 µm2 (P > 0.05, data not 
shown). Whereas, Mef2a Apoe deficient knockout mice showed a significant difference 
in the lesion formation. The major effects of Mef2a Apoe deficiency on lesion formation 
were observed in the proximal aorta. The lesions were increased by two fold in the 
heterozygotes (P = 0.0003).  The average size of lesions observed in the wild type males 
and females was 46621 µm2 and 61568 µm2, respectively and 83408 µm2 and         
137822 µm2 in the heterozygous males and females, respectively. Thus, there was a two 
fold increase of the lesion sizes among the heterozygous mice compared to wild type 
controls (P ≤ 0.0003). 
To identify a mechanism of the Mef2a+/ Apoe / effects on atherosclerosis, we 
speculated that Mef2a defect can cause dysfunctional or abnormally-developed 
endothelium. To test the hypothesis, we assessed the function of vascular permeability in 
the study group mice using miles assay.  
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Our findings showed a significant increase in the leakage of the dye from the 
stimulated ears of the Mef2a+/ Apoe /  mice compared to the wild type mice (P = 
0.000012 ) (Fig. 22). This experiment was repeated thrice to confirm our findings.  
At a mechanistic level, vascular leakage is linked to the infiltration of 
inflammatory particles responsible for causing atherosclerosis (87), hence our novel       
in vivo model may provide insights into the cause and effects of these genetic 
abnormalities. These results demonstrate a previously unrecognized function for Mef2a in 
basement membrane that is required for the maintenance of vascular permeability. Our 
findings are consistent with the studies on human patients who were heterozygous to the 
21bp deletion (29) and also to the other four single point mutations (33).   
We must acknowledge the difficulties in studying the homozygous double 
knockout mice (Mef2a-/-Apoe -/-). We observed 95% lethality in the Mef2a-/- Apoe-/- 
double knockout mice (the 5 % that survived also died before the end of the experimental 
period). Offspring from heterozygous intercrosses were born with the expected 
Mendelian distribution. However, most of the Mef2a-/-Apoe-/- pups born were smaller in 
size and died at P1 stage and few of the females that survived were, however, infertile. 
This fertility defect presumably could be from vasculature defects. Mef2a-/-Apoe-/- males 
had no obvious impairment in fertility. Mef2a+/-Apoe /  mice were generally healthy. 
Hence, all our experiments were carried with the Mef2a+/- Apoe-/- and Mef2a+/+Apoe-/- 
mice. We feel that these experiments are still representative of the intended phenotype, as 
reported mutations in human patients are heterozygous.  
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Our results have important implications for future investigations. First, the 
Mef2a+/  Apoe-/  mice provide an exciting genetic model of atherosclerosis. In the 
present study, we used this model to address the role of Mef2a on atherosclerosis, and this 
murine model will likely prove valuable for exploring the detailed molecular pathogenic 
mechanisms of CAD. In addition, the recognition of Mef2a as a molecular determinant of 
vascular permeability and atherosclerosis may provide insights to determine how a 
basement membrane regulates the permeability property of endothelium. 
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FUTURE INVESTIGATIONS 
 
The central finding of this dissertation is that Mef2a plays a key role in the 
development of CAD and MI in humans and also in mice. The initial linkage mapping 
and identification of the 21-bp deletion in the large CAD family laid the foundation for 
the studies in this thesis. This observation led us to the hypothesis that there could be 
various other mutations in Mef2a that are associated with CAD and MI.  Thus, we carried 
out screening of MEF2A in 407 CAD patients and 191 controls and identified four novel 
missense functional mutations. Our transcriptional activation assays suggest that the 7 
amino acid deletion in Mef2a acts by a dominant-negative mechanism and the missense 
mutations act by a loss-of-function mechanism.   
To further establish the association between MEF2A and CAD, we studied Mef2a 
knockout and Mef2a/Apoe double knockout mice. These studies have provided major 
insights into the role of the Mef2a gene in atherosclerosis. Our finding that heterozygous 
Mef2a knockout mice showed a 2-fold increase of atherosclerosis than wild type mice at 
the Apoe-/- background indicates that Mef2a deficiency causes atherosclerosis.  
Furthermore, we established that increased vascular permeability may be one mechanism 
for development of atherosclerosis in Mef2a+/- Apoe-/- mice. However, the detailed 
molecular mechanism by which MEF2A deficiency causes CAD/MI remain to be further 
explored. These studies are briefly discussed below: 
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A)  In vivo properties of mutant Mef2a in mouse models  
The development of mouse models for CAD based on Mef2a is the most 
convincing approach to validate the finding in human patients that Mef2a is a disease-
causing gene for CAD and to identify novel molecular mechanisms by which Mef2a 
causes CAD.  This was also the only feasible approach to study the in vivo physiological 
roles of Mef2a in the development of CAD. This will also be one of the best ways to test 
potential pharmacological and gene-based therapies that may benefit CAD patients with 
Mef2a mutations. The alternative method to the use of animals is to use coronary artery 
tissues from human subjects. However, such tissues are not available and studies with 
human subjects are highly risky and limited.  
Thus we proposed to study Mef2a deficient mice, along with its appropriate strain 
matched controls.  
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Vasculature and growth defects in knockout mice deficient in Mef2a 
The homozygous Mef2a-/- mice are susceptible to sudden death during the first 
week of life (32).  No structural heart defects were detected before the death, but dilation 
of the right ventricle was detected for the homozygous Mef2a-/- mice with sudden death at 
necropsy (32).  Mice that escaped the perinatal sudden death and reached adulthood are 
also susceptible to sudden death (32). The cause of the sudden death phenotype in 
homozygous Mef2a-/- mice remains largely unknown. Heterozygous Mef2a+/- mice 
exhibit an overall normal phenotype.  Potential phenotypic changes in coronary arteries 
and other vessels were not examined in Mef2a+/- or Mef2a-/- mice. In this study we 
examined the coronary arteries or other vessels to determine whether these mice showed 
any phenotype related to human CAD and MI. 
Mef2a+/- mice on the mixed background 129Sv/C57Bl6 were brother sister mated 
to generate three strain-matched groups of mice Mef2a +/+, +/-, and -/- in a 1:2:1 ratio.  
We examined the histology of the aortic root and coronary arteries in these 3 groups of 
mice, at P1, P2 and other stages of the pups that were alive and in those pups that have 
died suddenly. This study revealed interesting preliminary insights into development of 
Mef2a-/- mice. They were significantly smaller than the wild type mice and further studies 
on the heart showed distinct reduction or absence of coronary arteries. Initially we 
observed that the pups died at the P1 stage were very small and the pups might be born 
dead.  The genotyping results on the dead pups showed that they were homozygous mice. 
Hearts from the Mef2a+/- and Mef2a-/- mice were fixed in 4% paraformaldehyde 
overnight. After dehydration in a graded series of ethanol, they were paraffin embedded, 
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cut into serial sections (both cross-sections and longitudinal-sections), de-paraffinized 
and subjected to hematoxylin and eosin staining. This study was designed to detect any 
overall defects in the heart. 
 Figure 23 shows growth defects in the Mef2a homozygous mice. The homozygous 
mice showed extremely small size when born and died shortly after birth and a clear 
vasculature defects were physically seen.  
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A)  Mef2a wild type                    B) Mef2a homozygous- P1 stage  
       
Fig 23: Vasculature and growth defects in knockout mice deficient in Mef2a. 
Vascular and growth defects were observed in the mutant Mef2a mice compared to the 
wild type mice. 
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 The H&E staining of the hearts revealed that the mutant hearts had no blood.  
Coronary artery defects, and the absence of inter ventricular septum, ventricular chamber 
abnormalities were observed in Mef2a homozygous mice. Very few numbers of the blood 
vessels were observed in the homozygous mice. This is a preliminary investigation and 
further studies are required to confirm this finding (Fig 24-26). 
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A)  Mef2a Wild Type                                   B) Mef2a Homozygous- Heart 
                    Fig 24: Coronary artery defects in Mef2a knockout mice.  
The morphological appearance of mouse hearts, absence/very few of coronary 
arteries were seen in the  homozygous pup compared to wild type mice. 
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A)   Mef2a wild type                              B) Mef2a homozygous- heart 
   Fig25: H&E staining of saggital sections of mouse heart. 
 A) Wild type B) Homozygous. RA, right atrium; LA, left atrium; RV, right ventricle; IVS, 
Inter ventricular septum; LV, left ventricle; CA coronary arteries. Very few numbers of 
the blood vessels were observed in the homozygous mice. 
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                   A) Mef2a wild type                              B) Mef2a homozygous 
Fig 26: H&E staining of saggital sections of mouse hearts 
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 The histological studies of the coronary arteries and other vasculature of the 
Mef2a+/+ and Mef2a-/- pups revealed a reduced number of coronary arteries, or collapse of 
blood vessels (Fig 26) at higher magnification (40x), which might be leading to the lack 
of blood supply in these mice, causing the death of these mice at a very early age. A 
further systematic and in depth study will provide additional insights. 
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B)  In vivo properties of Mef2a and Apoe double knockout mice 
Vasculature and growth defects in Mef2a and Apoe double knockout mice 
 Mef2a+/-Apoe-/- mice on the mixed background were brother-sister mated to 
generate three strain-matched groups of mice Mef2a +/+, +/-, and -/- in a 1:2:1 ratio.  We 
examined the histology of the aortic root and coronary arteries in the 3 groups of mice at 
P1 and other stages that were alive and in those pups that died suddenly.                        
The Mef2a-/-Apoe-/- mice were significantly smaller than the wild type mice and further 
studies on the heart showed similar results as in the Mef2a-/- knockout mice (Fig 27). A 
detailed systematic and in depth study will provide additional insights. 
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               A) Mef2a +/+ Apoe -/-        B) Mef2a-/- Apoe-/- 
Fig 27: Vasculature and growth defects in deficient in Mef2a and Apoe double 
knockout mice. 
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 The double knockout mice also showed 90% lethality and the pups that were 
homozygous were small when compared to the wild type counterparts and also showed 
the absence of vasculature (Fig 27). These mice might be born dead or might have died at 
P1 stage just after birth. A possible explanation could be that in these mice vascular 
structure might not be developed completely, which could be causing the lack of blood 
supply and thereby leading to the death. A further detailed study is required to understand 
the possible mechanism behind this phenotype. 
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C) To identify downstream target genes affected by the Mef2a deletion in 
endothelial cells (ECs) and vascular smooth muscle cells (VSMCs) 
ECs and VSMCs will be isolated from Mef2A knockout mice using the following 
procedure. Thoracic aortas are isolated and 1-mm rings are cut and placed between two 
layers of Matrigel, supplemented with 20 U/ml heparin.  Microvessels grow out from the 
aortic rings and endothelial cells are recovered using a collagenase-containing 
dissociation buffer.  The murine endothelial cells are cultured as for HUVECs; however, 
for every other passage, they are plated onto Matrigel, rather than onto fibronectin, which 
appears to prolong the life of the cultures. VSMCs can also be isolated from the aortas by 
the enzyme-dispersed method (collagenase, type V, Sigma).   
The cells will be used to isolate RNA using Trizol reagent (Invitrogen) according 
to the manufacturer’s instructions. The RNA will be converted to cRNA for Affymetrix 
microarray analysis. Duplicate arrays will be performed. The microarray data will be 
analyzed as previously described by us (88). The microarray data will be confirmed by 
reverse-transcription PCR, Northern blot analysis, in situ hybridization, (88) or Western 
blot analysis if the antibody is available.   
These studies will lead to the identification of the genes regulated by Mef2a in 
ECs and VSMCs. Future studies can be designed to explore the biological functions of a 
selected group of genes in relation to CAD and MI. Some genes identified here will 
become very strong candidate genes for CAD and MI if they locate in the significant MI 
loci reported in the literature. Association studies can be carried out to test whether the 
candidate genes are associated with CAD and MI in humans.   
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C) Molecular and cellular properties of ECs and VSMCs from mutant Mef2a, 
Mef2a Apoe mice 
Because the coronary arteries are composed of two main cell types, endothelial 
cells (ECs) and vascular smooth muscle cells (VSMCs), we hypothesize that Mef2a plays 
a critical role in differentiation and function of these two types of cells, and Mef2a 
mutations may affect proliferation, apoptosis, or cell adhesion of ECs.   
Cell proliferation assay 
Many cell proliferation assay kits are commercially available. We can use 
Amersham Biosciences [3H] Thymidine Uptake Assay kit for cell proliferation assays.  
The principle for this assay is based on the close association between DNA synthesis and 
cell doubling (divided into two daughter cells). If [3H] thymidine is added to the cell 
culture, cells that are undergoing cell division will incorporate the labeled nucleotide into 
their DNA. The amount of [3H] thymidine incorporated into the cellular DNA is 
quantitated. The [3H] thymidine uptake assay system from Amersham Biosciences is 
based on a polyvinyltoluene bead containing scintillant.  The outer surface of the bead 
has been modified to enable only [3H] DNA to bind, which will generate a measurable 
light signal.        
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Apoptosis assay 
The apoptosis assay will be carried out to examine the difference fro ECs and 
VSMCs from wild type and mutant mice. This assay is to investigate if the Mef2a 
deficiency can induce apoptosis.  Apoptosis can be analyzed using a flow cytometry that 
detects DNA breaks labeled by fluorescein anti-BrdU antibody and total cellular DNA 
labeled by Propidium Iodide (APO-BRDU TM Kit; Pharmingen, San Diego, CA). The 
CCF LRI Flow Cytometry Core has necessary equipment for this assay.   
 
 
 
 
 
 
 
 
 
 
 
 
 107 
 
REFERENCES 
1 Wang Q, Chen Q (2000) Cardiovascular disease and congenital defects. Nature           
Encyclopedia of Life Sciences, A1907. 
 
2 Wang Q, Chen Q (2003) Cardiovascular disease and congenital heart defects. Nature 
Encyclopedia of Human Genome, 1, 396-411. 
 
3 Lewis D, Wang Q, Topol EJ (2002) Ischemic heart disease. Nature Encyclopedia of       
Life Sciences, 10, 508-515.  
 
4 American Heart Association (2003) American Heart Association. 
 
5 American Heart Association (2003) International cardiovascular disease statistics. 
American Heart Association. 
 
6 Lusis,A.J. (2000) Atherosclerosis. Nature, 407, 233-241.  
 
7 Nora,J.J., Lortscher,R.H., Spangler,R.D., Nora,A.H., Kimberling,W.J. (1980) 
Genetic--epidemiologic study of early-onset ischemic heart disease. Circulation, 61, 
503-508. 
 
8   Schildkraut,J.M., Myers,R.H., Cupples,L.A., Kiely,D.K., Kannel,W.B. (1989)    
Coronary risk associated with age and sex of parental heart disease in the 
Framingham Study. Am. J. Cardiol., 64, 555-559. 
 
9 Wang Q, Pyeritz RE (2000) Topol EJ (ed.), Textbook of Cardiovascular Medicine.    
Lippincott Williams & Wilkins, New York, NY, Vol. 3, pp. 1-12.  
 
 108 
 
10 Libby P, Theroux P. Pathophysiology of coronary artery disease. Circulation 
2005;111:3481– 8. 
 
11 Cybulsky MI, Gimbrone MA Jr. Endothelial expression of a mononuclear leukocyte 
adhesion molecule during atherogenesis. Science (Wash DC) 1991;251:788 –91. 
 
12 Li H, Cybulsky MI, Gimbrone MA Jr, Libby P. An atherogenic diet rapidly induces 
VCAM-1, a cytokine- regulatable mononuclear leukocyte adhesion molecule, in 
rabbit aortic endothelium. Arterioscler Thromb 1993;13:197–204. 
 
13 Cybulsky MI, Iiyama K, Li H, Zhu S, Chen M, Iiyama M, et al. A major role for 
VCAM-1, but not ICAM-1, in early atherosclerosis. J Clin Invest 2001;107:1255– 62. 
 
14 Skalen K, Gustafsson M, Rydberg EK, Hulten LM, Wiklund O, Innerarity TL, et al. 
Sub endothelial retention of atherogenic lipoproteins in early atherosclerosis. Nature 
(Lond) 2002;417:750–4. 
 
15 Kruth HS. Sequestration of aggregated low-density lipoproteins by macrophages. 
Curr Opin Lipidol 2002;13:483– 8. 
 
16 Williams KJ, Tabas I. The response-to-retention hypothesis of atherogenesis 
reinforced. Curr Opin Lipidol 1998;9:471– 4. 
 
17  Miller YI, Chang MK, Binder CJ, Shaw PX, Witztum JL. Oxidized low density 
lipoprotein and innate immune receptors. Curr Opin Lipidol 2003;14:437– 45. 
 
18 Amorino GP, Hoover RL. Interactions of monocytic cells with human endothelial 
cells stimulate monocytic metalloproteinase production. Am J Pathol 1998;152:199 –
207. 
 
 109 
 
19  Rajavashisth TB, Andalibi A, Territo MC, Berliner JA, Navab M, Fogelman AM, et 
al. Induction of endothelial cell expression of granulocyte and macrophage colony-
stimulating factors by modified low-density lipoproteins. Nature (Lond) 
1990;344:254 –7. 
 
20 Clinton SK, Underwood R, Hayes L, Sherman ML, Kufe DW, Libby P. Macrophage 
colonystimulating factor gene expression in vascular cells and in experimental and 
human atherosclerosis. Am J Pathol 1992;140:301–16. 
 
21 Libby P. Inflammation and cardiovascular disease mechanisms. Am J Clin Nutr 
2006;83: 456S– 460S. 
 
 
22 Libby P, Aikawa M. Stabilization of atherosclerotic plaques: new mechanisms and 
clinical targets. Nat Med 2002;8:1257– 62. 
 
23 Wang, Q., Rao, S., Shen, G.Q., Li, L., Moliterno, D.J., Newby, L.K., Rogers, W.J., 
Cannata, R., Zirzow, E., Elston, R.C. and Topol, E.J. (2004) Premature myocardial 
infarction novel susceptibility locus on chromosome 1P34–36 identified by 
genomewide linkage analysis. Am. J Hum. Genet. 74, 262–271. 
 
24  Broeckel, U., Hengstenberg, C., Mayer, B., Holmer, S., Martin, L.J., Comuzzie, 
A.G., Blangero, J., Nurnberg, P., Reis, A., Riegger, G.A. et al. (2002) A 
comprehensive linkage analysis for myocardial infarction and its related risk factors. 
Nat. Genet., 30, 210–214. 
 
25   Pajukanta, P., Cargill, M., Viitanen, L., Nuotio, I., Kareinen, A., Perola, M.,    
Terwilliger, J.D., Kempas, E., Daly, M., Lilja, H. et al. (2000) Two loci on 
chromosomes 2 and X for premature coronary heart disease identified in early- and   
late-settlement populations of Finland. Am. J.Hum. Genet., 67, 1481–1493. 
 
26   Harrap, S.B., Zammit, K.S., Wong, Z.Y., Williams, F.M., Bahlo, M.,Tonkin, A.M.  
and Anderson, S.T. (2002) Genome-wide linkage analysis of the acute coronary 
syndrome suggests a locus on chromosome 2.Arterioscler. Thromb. Vasc. Biol., 22, 
874–878. 
 
27  Hauser, E.R., Crossman, D.C., Granger, C.B., Haines, J.L., Jones, C.J., Mooser, V., 
McAdam, B., Winkelmann, B.R., Wiseman, A.H., Muhlestein, J.B. et al. (2004) A 
genomewide scan for early-onset coronary artery disease in 438 families: the 
GENECARD study. Am. J.Hum. Genet., 75, 436–447. 
 110 
 
 
28  Francke, S., Manraj, M., Lacquemant, C., Lecoeur, C., Lepretre, F.,Passa, P., Hebe, 
A., Corset, L., Yan, S.L., Lahmidi, S. et al. (2001) A genome-wide scan for coronary 
heart disease suggests in Indo-Mauritians a susceptibility locus on chromosome 
16p13 and replicates linkage with the metabolic syndrome on 3q27. Hum. Mol. 
Genet., 10, 2751–2765. 
 
29 Wang, L., Fan, C., Topol, S.E., Topol, E.J. and Wang, Q. (2003) Mutation of MEF2A 
in an inherited disorder with features of coronary artery disease. Science, 302, 1578–
1581. 
 
30  Black, B.L., Molkentin, J.D. and Olson, E.N. (1998) Multiple roles for the MyoD 
basic region in transmission of transcriptional activation signals and interaction with 
MEF2. Mol. Cell. Biol., 18, 69–77. 
 
31 McKinsey, T.A., Zhang, C.L. and Olson, E.N. (2002) MEF2: a calciumdependent 
regulator of cell division, differentiation and death. Trends Biochem. Sci., 27, 40–47. 
 
32  Naya, F.J., Black, B.L., Wu, H., Bassel-Duby, R., Richardson, J.A., Hill, J.A. and 
Olson, E.N. (2002) Mitochondrial deficiency and cardiac sudden death in mice 
lacking the MEF2A transcription factor. Nat. Med., 8,1303–1309. 
 
33 Bhagavatula MR, Fan C, Shen GQ et al. Transcription factor MEF2A mutations in 
patients with coronary artery disease. Hum Mol Genet 2004; 13(24):3181-3188. 
 
34 Weng, L. et al.  Lack of MEF2A mutations in coronary artery disease. J. Clin. Invest. 
2005;115:1016-1020.         
 
35 Qing Wang, Shaoqi Rao and Eric J. Topol .Miscues on the "lack of MEF2A 
mutations" in Coronary Artery Disease. J Clin Invest. 2005 Jun;115(6):1399-400. 
 
36 Gonzalez P,Garcia-Castro M et al.The Pro279Leu variant in the transcription factor 
MEF2A is associated with myocardial infacrction. J Med. Genet. 2005 June 15. 
 
37 Quinn, ZA Yang, CC, Wrana, JL et al. Smad proteins function as co-modulators for 
MEF2 transcriptional regulatory proteins. Nucleic Acids Research 2001; 29:732-742. 
 
 111 
 
38 Bruneau, BG, Bao, ZZ, Tanaka, M, et al. Cardiac expression of the ventricle-specific   
homeobox gene Irx4 is modulated by Nkx2-5 and dHand. Dev. Biol. 2000;217: 266–
277. 
 
39  Bi, W, Drake, CJ, and Schwarz, JJ. The transcription factor MEF2C-null mouse 
exhibits complex vascular malformations and reduced cardiac expression of 
angiopoietin 1 and VEGF. Dev. Biol. 1999; 211: 255–267. 
 
40 Lin, Q, Schwarz, J,  Bucana, C. et al. Control of mouse cardiac morphogenesis and 
myogenesis by transcription factor MEF2C. Science 1997;276:1404–1407. 
 
41 Lyons, GE, Micales, BK, Schwarz, J, et al. Expression of mef2 genes in the mouse 
central nervous system suggests a role in neuronal maturation. J. Neurosci. 
1995;15:5727–5738. 
 
42 Edmondson, DG, Lyons,GE, Martin, JF, et al. Mef2 gene expression marks the 
cardiac and skeletal muscle lineages during mouse embryogenesis. Development 
1994;120:1251–1263.  
 
43 Swanson, BJ, Jack, HM and Lyons, GE. Characterization of myocyte enhancer factor 
2 (MEF2) expression in B and T cells: MEF2C is a B cell-restricted transcription 
factor in lymphocytes. Mol. Immunol. 1998;35: 445–458. 
 
44 Buchberger, A. and Arnold, HH. The MADS domain containing transcription factor 
cMef2a is expressed in heart and skeletal muscle during embryonic chick 
development. Dev. Genes Evol. 1999;209: 376–381. 
 
45 Black ,BL and Olson, EN. Transcriptional control of muscle development by myocyte 
enhancer factor-2 (MEF2) proteins. Annu. Rev. Cell. Dev. Biol., 1998;14: 167–196. 
 
46 Youn, HD, Sun, L, Prywes, R et al.Apoptosis of T cells mediated by Ca2+-induced 
release of the transcription factor MEF2. Science 1999; 286: 790–793. 
 
47 Zhao, M, New, L, Kravchenko, VV et al. Regulation of the MEF2 family of 
transcription factors by p38. Mol. Cell. Biol., 1999; 19: 21–30. 
 
48 Han, J, Jiang, Y, Li, Z, et al. Activation of the transcription factor MEF2C by the 
MAP kinase p38 in inflammation. Nature, 1997;386:296–299.      
 112 
 
 
49 Yang, CC, Ornatsky, OI, McDermott, JC, et al. Interaction of myocyte enhancer 
factor 2 (MEF2) with a mitogen-activated protein kinase, ERK5/BMK1. Nucleic 
Acids Res. 1999;26: 4771–4777.       
 
50 Ornatsky, OI, Cox, DM, Tangirala, P, et al. Post-translational control of the MEF2A 
transcriptional regulatory protein. Nucleic Acids Res., 1999;27:646–265.  
 
51 Hidaka K, Morisaki T, Byun SH, et al. The MEF2B homologue differentially 
expressed in mouse embryonal carcinoma cells. Biochem Biophys Res Commun. 
1995;213: 555-560. 
 
52 Allen MP, Xu M, Zeng C, et al. Myocyte enhancer factors-2B and -2C are required 
for adhesion related kinase repression of neuronal gonadotropin releasing hormone 
gene expression. 2000; J Biol Chem. 275: 39662-39670. 
 
53 Molkentin JD, Firulli AB, Black BL, et al. MEF2B is a potent transactivator 
expressed in early myogenic lineages. Mol Cell Biol. 1996;16, 3814-3824. 
 
54  Han A, He J, Wu Y, et al. Mechanism of recruitment of class II histone deacetylases 
by myocyte enhancer factor-2. J Mol Biol. 2005;345(1), 91-102. 
 
55 Zhao M, New L, Kravchenko VV, et al. Regulation of the MEF2 family of 
transcription factors by p38. Mol Cell Biol. 1999;19: 21-30.  
 
56 Kato Y, Zhao M, Morikawa A, et al. Big mitogen-activated kinase regulates multiple 
members of the MEF2 protein family. J Biol Chem. 2000;275: 18534-18540. 
 
57 Han A, Pan F, Stroud JC, et al. Sequence-specific recruitment of transcriptional co-
repressor Cabin1 by myocyte enhancer factor-2.  Nature. 2003;422, 730-4. 
 
 113 
 
58 Dodou E, Verzi MP, Anderson JP, Xu SM, Black BL. Mef2c is a direct 
transcriptional target of ISL1 and GATA factors in the anterior heart field during 
mouse embryonic development. Development. 2004;13:3931-42. 
 
59 Edmondson DG, Lyons GE, Martin JF, Olson EN. Mef2 gene expression marks the 
cardiac and skeletal muscle lineages during mouse embryogenesis. Development. 
1994 120:1251-63.  
 
60 Lin Q, Lu J, Yanagisawa H, Webb R, Lyons GE, Richardson JA, Olson 
EN.Requirement of the MADS-box transcription factor MEF2C for vascular 
development. Development. 1998;125(22):4565-74. 
 
61 Bi W, Drake CJ, Schwarz JJ. The transcription factor MEF2C-null mouse exhibits 
complex vascular malformations and reduced cardiac expression of angiopoietin 1 
and VEGF. Dev Biol. 1999;211:255-67. 
 
62 Liu L, Cavanaugh JE, Wang Y, et al. ERK5 activation of MEF2-mediated gene 
expression plays a critical role in BDNF-promoted survival of developing but not 
mature cortical neurons. Proc Natl Acad Sci U S A. 2003;100:8532-7. 
 
63  Linseman DA, Bartley CM, Le SS, et al. Inactivation of the myocyte enhancer 
factor-2 repressor histone deacetylase-5 by endogenous Ca(2+) //calmodulin-
dependent kinase II promotes depolarization-mediated cerebellar granule neuron 
survival. J Biol Chem. 2003 278:41472-81.  
 
64 Mao Z, Bonni A, Xia F, et al. Neuronal activity-dependent cell survival mediated by 
transcription factor MEF2. Science. 1999;28:785-90. 
 
65 Hayashi M, Kim SW, Imanaka-Yoshida K, et al.Targeted deletion of BMK1/ERK5 in 
adult mice perturbs vascular integrity and leads to endothelial failure. J Clin Invest. 
2004 Apr;113:1138-48. 
 
 114 
 
66 Woronicz, J. D., Calnan, B., Ngo, V. and Winoto, A. Requirement for the orphan 
receptor Nur77 in apoptosis of T-cell hybridomas. Nature 1994;367: 277-281. 
 
67 Liu, Z. G., Smith, S. W., McLaughlin, K. A., et al. A. Apoptotic signals delivered 
through the T-cell receptor of a T-cell hybrid require the immediate-early gene 
Nur77. Nature 1994;367, 281-284. 
 
68 Chen, S., Zhang, L., Bryant, R.M., Vincent, G.M., Flippin, M., Lee, J.C.,Brown, E., 
Zimmerman, F., Rozich, R., Szafranski, P. et al. (2003) KCNQ1 mutations in patients 
with a family history of lethal cardiac arrhythmias and sudden death. Clin. Genet., 63, 
273–282. 
 
69 Chen, Q., Kirsch, G.E., Zhang, D., Brugada, R., Brugada, J., Brugada, P., Potenza, 
D., Moya, A., Borggrefe, M., Breithardt, G. et al. (1998) Genetic basis and molecular 
mechanism for idiopathic ventricular fibrillation. Nature, 392, 293–296. 
 
70  Wang, Q., Shen, J., Li, Z., Timothy, K., Vincent, G.M., Priori, S.G., Schwartz, P.J. 
and Keating, M.T. (1995) Cardiac sodium channel mutations in patients with long QT 
syndrome, an inherited cardiac arrhythmia. Hum. Mol. Genet., 4, 1603–1607. 
 
71  Wang, Q., Shen, J., Splawski, I., Atkinson, D., Li, Z., Robinson, J.L., Moss, A.J., 
Towbin, J.A. and Keating, M.T. (1995) SCN5A mutations associated with an 
inherited cardiac arrhythmia, long QT syndrome. Cell, 80, 805–811. 
 
72 Wang, Q., Curran, M.E., Splawski, I., Burn, T.C., Millholland, J.M., VanRaay, T.J., 
Shen, J., Timothy, K.W., Vincent, G.M., de Jager, T. et al. (1996) Positional cloning 
of a novel potassium channel gene: KVLQT1 mutations cause cardiac arrhythmias. 
Nat. Genet., 12, 17–23.3188 Human Molecular Genetics, 2004, Vol. 13, No. 24. 
 
73 Wu L, Nishiyama K, Hollyfield JG et al. Localization of Nav1.5 sodium channel 
protein in the mouse brain. NeuroReport. 2002;13:2547-2551. 
 115 
 
74  Fan C, Duhagon MA, Oberti C et al. Novel TBX5 mutations and molecular 
mechanism for Holt-Oram syndrome. J Med Genet. 2003;40:e29. 
 
75 Fan C, Liu M, Wang Q. Functional analysis of TBX5 missense mutations associated 
with Holt-Oram syndrome. J Biol Chem. 2003;278:8780-8785. 
 
76 Dansky HM, Charlton SA, Sikes JL et al. Genetic background determines the extent 
of atherosclerosis in ApoE-deficient mice. Arterioscler Thromb Vasc Biol. 
1999;19:1960-1968.  
 
77 Smith JD, Dansky HM, Breslow JL. Genetic modifiers of atherosclerosis in mice. 
Ann N Y Acad Sci. 2001;947:247-252. 
 
78 Smith JD, James D, Dansky HM et al. In silico quantitative trait locus map for 
atherosclerosis susceptibility in apolipoprotein E-deficient mice. Arterioscler Thromb 
Vasc Biol. 2003;23:117-122. 
 
79 Han,E.D., mac Farlene,R.C., Mulligan, A.N., Scafidi, J.& Davis, A.E.,III. Increased 
vascular permeability in C1-inhibitor deficient mice mediated by the bradykinin type 
2 receptor. J.Clin.Invest. 109. 2002; 1057-1063  
 
80 Dansky HM, Charlton SA, Harper MM et al. T and B lymphocytes play a minor role 
in atherosclerotic plaque formation in the apolipoprotein E-deficient mouse. Proc Natl 
Acad Sci U S A. 1997;94:4642-4646. 
 
81 Dansky HM, Fisher EA. High-density lipoprotein and plaque regression: the good 
cholesterol gets even better. Circulation. 1999;100:1762-1763.  
 
82 Chen, S., Zhang, L., Bryant, R.M., Vincent, G.M., Flippin, M., Lee, J.C., Brown, E., 
Zimmerman, F., Rozich, R., Szafranski, P. et al. 2003;  KCNQ1 mutations in patients 
with a family history of lethal cardiac arrhythmias and sudden death. Clin. Genet., 63, 
273–282. 
 116 
 
83 Yong, S., Tian, X. and Wang, Q. (2003) LQT4 gene: the missing ankyrin. Mol. 
Interven., 3, 131–136. 
 
84  Sanguinetti, M.C., Curran, M.E., Spector, P.S. and Keating, M.T. (1996) Spectrum of 
HERG K þ -channel dysfunction in an inherited cardiacarrhythmia. Proc. Natl Acad. 
Sci. USA, 93, 2208–2212. 
 
85 Wang, Z., Tristani-Firouzi, M., Xu, Q., Lin, M., Keating, M.T. and Sanguinetti, M.C. 
(1999) Functional effects of mutations in KvLQT1 that cause long QT syndrome. J. 
Cardiovasc. Electrophysiol.,10, 817–826. 
 
86 Shalaby, F.Y., Levesque, P.C., Yang, W.P., Little, W.A., Conder, M.L., Jenkins-
West, T. and Blanar, M.A. (1997) Dominant-negative KvLQT1 mutations underlie 
the LQT1 form of long QT syndrome. Circulation, 96, 1733–1736. 
 
87 A. Wayne Orr, Rebecca Stockton, et al. Matrix-specific p21-activated kinase 
activation regulates vascular permeability in atherogenesis. The Journal of Cell 
Biology, Vol. 176, No. 5, 2007; 719–727 
 
88 Stephen A, Qing W. Expression profiling of cardiovascular disease. Hum Genomics. 
2004;1(5); 355-70. 
 
 
